var title_f11_55_12144="Paratracheal mass MRI I";
var content_f11_55_12144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal mass due to primary lung adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted section demonstrates a right paratracheal mass (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12144=[""].join("\n");
var outline_f11_55_12144=null;
var title_f11_55_12145="Anacardiaceae dermatitis";
var content_f11_55_12145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of anacardiaceae dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Acute, streak-like edematous and erythematous dermatitis without vesicles after poison ivy brushed across the face. Courtesy of Fitzsimons Army Medical Center Dermatology slide teaching library. B) Acute, streak- like vesicular dermatitis after poison ivy (Toxicodendron radicans) contact. Courtesy of Fitzsimons Army Medical Center Dermatology slide teaching library. C) \"Black-spot\" poison ivy dermatitis: note the black discoloration in the central portion of the edematous plaques due to plant resin. D) Widespread erythema and edema associated with intense pruritus after carrying logs of the poisonwood tree (Metopium toxiferum) of the family Anacardiaceae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12145=[""].join("\n");
var outline_f11_55_12145=null;
var title_f11_55_12146="Undecylenic acid and derivatives: Drug information";
var content_f11_55_12146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Undecylenic acid and derivatives: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30179?source=see_link\">",
"    see \"Undecylenic acid and derivatives: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11890?source=see_link\">",
"    see \"Undecylenic acid and derivatives: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fungi-Nail&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tinea and dermatophyte infections (superficial):",
"     </b>",
"     Topical: Apply twice daily to affected area for 4 weeks; apply to clean, dry area",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F235844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11890?source=see_link\">",
"      see \"Undecylenic acid and derivatives: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fungi-Nail&reg;: Undecylenic acid 25% (29.57 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of athlete's foot (tinea pedis); ringworm (except nails and scalp)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F235838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to undecylenic acid or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F235829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for self-medication (OTC use) in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes. Apply to clean, dry skin. When used for self-medication (OTC use), contact health care provider if condition does not improve within 4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Hongo Cura Anti-Fungal External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (60 mL): $3.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fungi-Nail External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (1.7 mL): $6.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5549684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Derman (MX);",
"     </li>",
"     <li>",
"      Micotex (MX)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10306 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12146=[""].join("\n");
var outline_f11_55_12146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235845\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235841\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235844\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235842\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235826\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235836\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235838\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235829\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300194\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223585\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324112\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5549684\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30179?source=related_link\">",
"      Undecylenic acid and derivatives: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11890?source=related_link\">",
"      Undecylenic acid and derivatives: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_55_12147="NSCLC malig pl eff post rx";
var content_f11_55_12147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image of the effusion following thoracentesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12147=[""].join("\n");
var outline_f11_55_12147=null;
var title_f11_55_12148="Mitochondrial pathways";
var content_f11_55_12148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Metabolic reactions in the mitochondria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12148=[""].join("\n");
var outline_f11_55_12148=null;
var title_f11_55_12149="Bicalutamide: Patient drug information";
var content_f11_55_12149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bicalutamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/2/30758?source=see_link\">",
"     see \"Bicalutamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Casodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bicalutamide&reg;;",
"     </li>",
"     <li>",
"      Ava-Bicalutamide;",
"     </li>",
"     <li>",
"      Casodex&reg;;",
"     </li>",
"     <li>",
"      CO Bicalutamide;",
"     </li>",
"     <li>",
"      Dom-Bicalutamide;",
"     </li>",
"     <li>",
"      JAMP-Bicalutamide;",
"     </li>",
"     <li>",
"      Mylan-Bicalutamide;",
"     </li>",
"     <li>",
"      Novo-Bicalutamide;",
"     </li>",
"     <li>",
"      PHL-Bicalutamide;",
"     </li>",
"     <li>",
"      PMS-Bicalutamide;",
"     </li>",
"     <li>",
"      PRO-Bicalutamide;",
"     </li>",
"     <li>",
"      ratio-Bicalutamide;",
"     </li>",
"     <li>",
"      Sandoz-Bicalutamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bicalutamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lowered interest in sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11312 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12149=[""].join("\n");
var outline_f11_55_12149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141228\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028887\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028889\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028888\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028893\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028894\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028896\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028891\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028892\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028897\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028898\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/2/30758?source=related_link\">",
"      Bicalutamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_55_12150="Pathophysiology, transmission, and natural history of syphilis";
var content_f11_55_12150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, transmission, and natural history of syphilis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12150/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12150/contributors\">",
"     Charles B Hicks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12150/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12150/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12150/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12150/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/55/12150/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is a chronic infection caused by the bacterium Treponema pallidum. The manifestations of disease are notoriously protean, occurring in any one individual in different stages over time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/1\">",
"     1",
"    </a>",
"    ]. First described at least 500 years ago, syphilis has a fascinating and diverse history [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/2\">",
"     2",
"    </a>",
"    ]. Studies performed in the preantibiotic era, some of which are now quite notorious, permit a relatively complete understanding of the natural history of untreated syphilis.",
"   </p>",
"   <p>",
"    The microbiology, pathophysiology, and natural history of syphilis will be reviewed here. The clinical manifestations, diagnosis, treatment, and follow-up of each of the various stages of syphilis are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treponema pallidum is a bacterium from the order Spirochaetales and is one of several closely related treponemes, which cause human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/3\">",
"     3",
"    </a>",
"    ]. T. pallidum is approximately 10 to 13 microns long but only 0.15 microns in width, making it too slender to be visualized by direct microscopy. This feature greatly complicates diagnosis.",
"   </p>",
"   <p>",
"    The organism can be seen with darkfield microscopy, a technique that employs a special condenser that casts an oblique light. When visualized by this method, T. pallidum is a delicate, corkscrew-shaped organism with tightly wound spirals (",
"    <a class=\"graphic graphic_picture graphicRef56211 \" href=\"UTD.htm?27/58/28590\">",
"     picture 1",
"    </a>",
"    ). It exhibits a characteristic rotary motion with flexing and back-and-forth movement, features considered sufficiently characteristic to be diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The understanding of T. pallidum pathophysiology is impeded by the inability to grow the organism in culture. Thus, knowledge of the growth characteristics and metabolism of this bacterium are quite limited. Data in animal models and human volunteers form the basis of most of the available information on this pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early local infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treponema pallidum initiates infection when it gains access to subcutaneous tissues via microscopic abrasions that occur during sexual intercourse. Despite a slow estimated dividing time of 30 hours, the spirochete evades early host immune responses and establishes the initial ulcerative lesion, the chancre (",
"    <a class=\"graphic graphic_picture graphicRef75291 \" href=\"UTD.htm?17/16/17664\">",
"     picture 2",
"    </a>",
"    ). During the period of early local replication, some organisms establish infection in regional draining lymph nodes, with subsequent dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood. The host immune response begins with lesional infiltration of polymorphonuclear leukocytes, which are soon replaced by T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study of 23 patients with secondary syphilis, leukocytes were obtained from syphilitic lesions and peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/7\">",
"     7",
"    </a>",
"    ]. Compared with peripheral blood, lesional fluids were enriched for CD4+ and CD8+ T cells, activated monocytes, macrophages, and dendritic cells. Many of these dendritic cells also expressed HIV coreceptors (eg, CCR5 and DC-SIGN), which may help explain the epidemiologic link between syphilis and HIV transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link&amp;anchor=H12#H12\">",
"     \"Factors affecting HIV progression\", section on 'Coreceptor usage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some respects, the immune response to T. pallidum is paradoxical. On one hand, the various immune responses during early infection appear to be efficacious, since they coincide with resolution of the primary chancre, even in the absence of therapy. Despite this apparent immune control, however, widespread dissemination of spirochetes occurs at the same time, leading to subsequent clinical manifestations of secondary or tertiary syphilis in untreated patients.",
"   </p>",
"   <p>",
"    After acquisition on T. pallidum, humoral immune responses are generated, leading to the development of a variety of antibodies that can be detected relatively early in the course of syphilis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all new syphilis infections are sexually acquired, except for cases resulting from vertical transmission (ie, infection acquired in utero or during delivery). Syphilis is transmissible during early disease (primary and secondary syphilis) with an efficiency of transmission estimated at approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission requires exposure to open lesions with organisms present, features seen with the primary chancre and with some elements of secondary syphilis, including mucocutaneous lesions. The organism can initiate infection wherever inoculation occurs; contact of infected secretions with almost any tissue can lead to a primary syphilis lesion at that site (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period varies from 10 to 90 days (average about three weeks), being shorter with larger inocula [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF UNTREATED SYPHILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evolution of syphilis was relatively well appreciated even before the infectious origin of the disease was known. Identification of the causative organism, Treponema pallidum, in 1905 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/9\">",
"     9",
"    </a>",
"    ], and development of the first serologic test for the disease shortly thereafter, afforded an even more complete understanding.",
"   </p>",
"   <p>",
"    Information about the natural history of untreated syphilis in humans derives from data collected from several sources.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the late 19th century, a Norwegian physician described the evolution of infection in more than 1400 patients with primary and secondary syphilis. Because he believed that the available therapies at the time were highly toxic and of little benefit, patients received no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional data were collected from a study of 382 adults with syphilis who underwent autopsies between 1917 and 1941 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/11\">",
"       11",
"      </a>",
"      ]. This compilation provided pathologic confirmation of the late manifestations of syphilis.",
"     </li>",
"     <li>",
"      Finally, the infamous Tuskegee study conducted between 1932 and 1972 collected data on 431 black men whose syphilis was untreated [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there are limitations to all of these studies, an understanding of the natural history of syphilis can be reasonably well constructed based upon analysis of these data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRIMARY SYPHILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following acquisition of T. pallidum, the initial clinical manifestations are termed primary syphilis and usually consist of a chancre at the site of inoculation (",
"    <a class=\"graphic graphic_picture graphicRef75291 \" href=\"UTD.htm?17/16/17664\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chancre represents an initial local infection, but syphilis quickly becomes systemic with widespread dissemination of the spirochete. Since most chancres are painless, many persons with primary syphilis do not come to medical attention. Even without treatment, chancres usually heal within a few weeks. The painless nature of the chancre distinguishes it from the two other major causes of a genital ulcer, herpes simplex (genital herpes) and Hemophilus ducreyi (chancroid), although there is considerable variability among patients, and the presence or absence of pain is not always a reliable clinical clue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SECONDARY SYPHILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weeks to a few months later, approximately 25 percent of individuals with untreated infection develop a systemic illness that represents secondary syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with secondary syphilis may not have a history of a preceding chancre since the primary infection may have been asymptomatic or gone unnoticed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary syphilis can produce a wide variety of symptoms including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A rash (the most characteristic finding)",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Malaise",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Diffuse lymphadenopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rash typically involves the palms and soles (",
"    <a class=\"graphic graphic_picture graphicRef68877 \" href=\"UTD.htm?9/3/9279\">",
"     picture 3",
"    </a>",
"    ), but it may also include mucosal surfaces (",
"    <a class=\"graphic graphic_picture graphicRef66087 \" href=\"UTD.htm?42/15/43251\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/12\">",
"     12",
"    </a>",
"    ]. Lesions may be maculopapular, papular, annular, or even pustular. In one series of 105 patients with secondary syphilis, more than 20 percent had lesions that were not appreciated by the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/12\">",
"     12",
"    </a>",
"    ]. In HIV-infected patients, a more severe ulcerative form of secondary syphilis termed \"lues maligna\" has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/13\">",
"     13",
"    </a>",
"    ]. It occurs principally in persons with severely compromised immune systems and presents with non-resolving severe ulcerative skin lesions (",
"    <a class=\"graphic graphic_picture graphicRef50771 \" href=\"UTD.htm?32/52/33603\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sometimes underappreciated manifestation of secondary syphilis is eye involvement. Ocular syphilis can involve almost any eye structure, but most commonly causes posterior uveitis and presents with diminished visual acuity (",
"    <a class=\"graphic graphic_picture graphicRef68210 \" href=\"UTD.htm?12/19/12593\">",
"     picture 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Ocular syphilis may be more common among persons who are HIV-infected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/15\">",
"     15",
"    </a>",
"    ]. Involvement of the eye in patients with syphilis should be considered a manifestation of neurosyphilis and managed accordingly.",
"   </p>",
"   <p>",
"    Similar to primary disease, the acute manifestations of secondary syphilis typically resolve spontaneously, even in the absence of therapy (except in the case of lues maligna). Occasional untreated patients experience additional episodes of relapsing secondary syphilis for up to five years after their initial episode [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LATENT SYPHILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latent syphilis refers to the period during which patients infected with T. pallidum have no symptoms but have infection demonstrable by serologic testing. Based upon the likelihood of spontaneous mucocutaneous relapses, this period has classically been separated into two categories: early latent and late latent syphilis. Patients in the early latent period are believed to be potentially infectious in contrast to late latency when transmission is no longer likely.",
"   </p>",
"   <p>",
"    However, it is a challenge to document that the syphilis infection was acquired within the previous year. Early latent syphilis can be diagnosed if local or state health department records, or the patient's medical records, document a negative serologic test for syphilis within the previous 12-month period with a current reactive serologic test; alternatively latent syphilis can be diagnosed if a fourfold titer increase in the non-treponemal antibody titer has occurred within the previous 12 months. Most often, the results of past serologic tests are not readily available and the diagnosis of \"syphilis of unknown duration\" is made.",
"   </p>",
"   <p>",
"    The United States Public Health Service (USPHS) has modified this definition by categorizing early latent syphilis as infection of one year's duration or less. All other cases are referred to as late latent syphilis or latent syphilis of unknown duration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/16\">",
"     16",
"    </a>",
"    ]. The USPHS recommends a longer duration of therapy for patients with late latent syphilis, based upon the notion that the biology of the spirochete evolves over time. In late latent syphilis, T. pallidum is thought to have a slower metabolism and a more prolonged dividing time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LATE SYPHILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients are untreated during the earlier stages of syphilis, they are at risk for the major complications of the infection, a diverse group of manifestations grouped together as late syphilis or tertiary syphilis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .) The clinical events occurring as a consequence of late syphilis may appear at any time from 1 to 30 years after primary infection and may involve a wide variety of different tissues. It is not necessary for individuals to have experienced clinically symptomatic primary or secondary syphilis prior to developing late syphilis.",
"   </p>",
"   <p>",
"    The most common manifestations of late syphilis are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central nervous system involvement (neurosyphilis, particularly general paresis and tabes dorsalis)",
"     </li>",
"     <li>",
"      Cardiovascular syphilis (especially aortitis)",
"     </li>",
"     <li>",
"      Gummatous syphilis (granulomatous, nodular lesions which can occur in a variety of organs, most commonly skin and bones)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with untreated syphilis may have a risk of tertiary syphilis that approaches 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/11\">",
"     11",
"    </a>",
"    ]. Most studies suggest the incidence of clinically recognized tertiary syphilis among untreated patients is closer to 25 percent. In the Oslo study of patients with untreated syphilis, 10 percent developed cardiovascular syphilis, 16 percent developed gummatous syphilis, and 6.5 percent developed symptomatic neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12150/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"       \"Patient information: Syphilis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15132379\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syphilis is a chronic infection caused by the bacterium Treponema pallidum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treponema pallidum is a delicate, corkscrew-shaped organism with tightly wound spirals, which exhibits a characteristic rotary motion seen on darkfield microscopy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treponema pallidum gains access to subcutaneous tissues via microscopic abrasions that occur during sexual intercourse. Despite a slow estimated dividing time of 30 hours, the spirochete evades early host immune responses and establishes the initial ulcerative lesion, the chancre. During the period of early local replication, some organisms establish infection in regional draining lymph nodes, with subsequent dissemination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all new syphilis infections are sexually acquired, except for cases resulting from vertical transmission (ie, infection acquired in utero or during delivery). Syphilis is transmissible during primary or secondary syphilis with an efficiency of transmission estimated at approximately 30 percent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following acquisition of T. pallidum, the initial clinical manifestations of primary syphilis consist of a painless chancre at the site of inoculation, which usually heals within a few weeks, even if untreated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Primary syphilis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Weeks to a few months later, approximately 25 percent of individuals with untreated primary infection develop secondary syphilis characterized by systemic symptoms including fever, rash, headache, malaise, anorexia and diffuse lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Secondary syphilis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients who have Treponema pallidum infection by serologic testing alone have &ldquo;latent syphilis&rdquo;. Patients in the early latent period (within one year of primary infection) are believed to be potentially infectious in contrast to late latency when transmission is no longer likely. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Latent syphilis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When patients are untreated during the earlier stages of syphilis, they are at risk for major complications involving the central nervous system or cardiovascular structures or granulomatous disease of the skin or bones. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Late syphilis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/1\">",
"      Hook EW 3rd, Marra CM. Acquired syphilis in adults. N Engl J Med 1992; 326:1060.",
"     </a>",
"    </li>",
"    <li>",
"     Sparling PF. Natural history of syphilis. In: Sexually Transmitted Diseases, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.213.",
"    </li>",
"    <li>",
"     Musher DM. Biology of Treponema pallidum. In: Sexually Transmitted Diseases, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/4\">",
"      Larsen SA. Syphilis. Clin Lab Med 1989; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/5\">",
"      MAGNUSON HJ, THOMAS EW, OLANSKY S, et al. Inoculation syphilis in human volunteers. Medicine (Baltimore) 1956; 35:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/6\">",
"      Baker-Zander S, Sell S. A histopathologic and immunologic study of the course of syphilis in the experimentally infected rabbit. Demonstration of long-lasting cellular immunity. Am J Pathol 1980; 101:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/7\">",
"      Salazar JC, Cruz AR, Pope CD, et al. Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis. J Infect Dis 2007; 195:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/8\">",
"      ROCKWELL DH, YOBS AR, MOORE MB Jr. THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION. Arch Intern Med 1964; 114:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/9\">",
"      Schaudinn FR, Hoffmann E. Vorlaufiger bericht uber das vorkommen von spirochaeten in syphilitischen krakheitsproducten und bei papillomen. Arbeiten aus dem K gesundheitsamte 1905; 22:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/10\">",
"      Clark EG, Danbolt N. The Oslo study of the natural course of untreated syphilis: An epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material. Med Clin North Am 1964; 48:613.",
"     </a>",
"    </li>",
"    <li>",
"     Rosahn PD. Autopsy studies in syphilis. 649 Information supplement #21, J Venereal Disease; U.S. Public Health Service Venereal Disease Division, Washington, DC 1947.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/12\">",
"      Chapel TA. The signs and symptoms of secondary syphilis. Sex Transm Dis 1980; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/13\">",
"      D'Amico R, Zalusky R. A case of lues maligna in a patient with acquired immunodeficiency syndrome (AIDS). Scand J Infect Dis 2005; 37:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/14\">",
"      Durnian JM, Naylor G, Saeed AM. Ocular syphilis: the return of an old acquaintance. Eye (Lond) 2004; 18:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/15\">",
"      Balba GP, Kumar PN, James AN, et al. Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy. Am J Med 2006; 119:448.e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12150/abstract/16\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7584 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12150=[""].join("\n");
var outline_f11_55_12150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15132379\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early local infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY OF UNTREATED SYPHILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRIMARY SYPHILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SECONDARY SYPHILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LATENT SYPHILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LATE SYPHILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15132379\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7584|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/58/28590\" title=\"picture 1\">",
"      Darkfield Treponema pallidum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/16/17664\" title=\"picture 2\">",
"      Penile chancre in syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/3/9279\" title=\"picture 3\">",
"      Rash in secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/15/43251\" title=\"picture 4\">",
"      Mucous patch secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/52/33603\" title=\"picture 5\">",
"      Lues maligna",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/19/12593\" title=\"picture 6\">",
"      Uveitis syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=related_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_55_12151="Terbutaline: Drug information";
var content_f11_55_12151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terbutaline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/42/26277?source=see_link\">",
"    see \"Terbutaline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"    see \"Terbutaline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14640925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or www.fda.gov.",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bricanyl&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Asthma or bronchoconstriction:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     5 mg/dose every 6 hours 3 times/day; if side effects occur, reduce dose to 2.5 mg every 6 hours; not to exceed 15 mg in 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: 0.25 mg/dose; may repeat in 15-30 minutes (maximum: 0.5 mg/4-hour period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unlabeled dose: 0.25 mg/dose; may repeat every 20 minutes for 3 doses (maximum: 0.75 mg/1-hour period) (NIH Guidelines, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Inhalation:",
"     </i>",
"     Bricanyl&reg; Turbuhaler&reg;: (Canadian labeling; not available in U.S.): One puff as needed; may repeat with 1 inhalation (after 5 minutes); more than 6 inhalations should not be necessary in any 24-hour period.",
"     <b>",
"      Note:",
"     </b>",
"     If adequate relief is not obtained with previously effective dose, or if effects of inhalation last &lt;3 hours, patient should be reassessed; may indicate worsening asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Premature labor (acute; short-term [&le;72 hours] tocolysis; unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     2.5-5 mcg/minute; increased gradually every 20-30 minutes by 2.5-5 mcg/minute; effective maximum dosages from 17.5-30 mcg/minute have been used with caution. Duration of infusion is at least 12 hours (Travis, 1993).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ:",
"     </i>",
"     0.25 mg every 20 minutes to 3 hours; hold for pulse &gt;120 beats per minute. Terbutaline has not been approved for and should not be used for prolonged tocolysis (beyond 48-72 hours) (ACOG, 2012; Hearne, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F225702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"      see \"Terbutaline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma or bronchoconstriction:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;12 years: Initial: 0.05 mg/kg/dose 3 times/day, increased gradually as required; maximum: 0.15 mg/kg/dose 3-4 times/day or a total of 5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12-15 years: 2.5 mg every 6 hours 3 times/day; not to exceed 7.5 mg in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;15 years: 5 mg/dose every 6 hours 3 times/day; if side effects occur, reduce dose to 2.5 mg every 6 hours; not to exceed 15 mg in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ:",
"     </i>",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;12 years: 0.005-0.01 mg/kg/dose to a maximum of 0.4 mg/dose every 15-20 minutes for 3 doses; may repeat every 2-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalation:",
"     </i>",
"     Bricanyl&reg; Turbuhaler&reg; (Canadian labeling; not available in U.S.): Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F225682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. The following adjustments have also been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:  Mild-to-severe impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute: Administer 50% of normal dose; avoid parenteral use in end-stage renal disease (ESRD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent hemodialysis: Administer after dialysis on days that patient undergoes hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis (PD): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15245730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Powder for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Bricanyl&reg; Turbuhaler&reg;: 500 mcg/actuation [100 or 200 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Use infusion pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer around-the-clock to promote less variation in peak and trough serum levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Bricanyl&reg; Turbuhaler&reg; (Canadian availability): After removing lid, patient should hold inhaler upright and turn blue grip as far as it will go in one direction then turn it back to original position. Clicking sound indicates that inhaler is ready for use. Patient should exhale fully but not into the inhaler and then place mouthpiece gently between teeth, close lips around inhaler and inhale deeply.  Inhaler should be removed from mouth prior to exhaling. Instruct patients to rinse mouth with water after each inhalation as some medication may stick to the inside of the mouth and throat. If inhaler is dropped or shaken, or if patient exhales into the inhaler after a dose is loaded, the dose will be lost and a new dose should be loaded and inhaled. Outside of mouthpiece should be cleaned once weekly with a dry tissue. Instruct patient to keep inhaler dry. First appearance of red mark in dose indicator (window underneath mouthpiece) indicates that 20 doses remain. When red mark reaches bottom of dose indicator no doses remain and Turbuhaler should be discarded.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F225732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Calcium gluconate, diltiazem, dobutamine, dopamine, epinephrine, insulin (regular), potassium chloride.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchodilator in reversible airway obstruction and bronchial asthma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F225721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Tocolytic agent (short-term [&le;72 hours] prevention or management  of preterm labor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F225734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Brethine may be confused with Methergine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Terbutaline may be confused with terbinafine, TOLBUTamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Terbutaline and methylergonovine parenteral dosage forms look similar. Due to their contrasting indications, use care when administering these agents.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum glucose increased, serum potassium decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Trembling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia, hypertension, pounding heartbeat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, lightheadedness, drowsiness, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dry mouth, nausea, vomiting, bad taste in mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arrhythmia, cardiac arrest (preterm labor), chest pain, hyperglycemia (preterm labor),  hypokalemia (preterm labor), hypotension (preterm labor), paradoxical bronchospasm, myocardial infarction (preterm labor), myocardial ischemia (preterm labor), pulmonary edema (preterm labor)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to terbutaline or any component of the formulation; cardiac arrhythmias associated with tachycardia; tachycardia caused by digitalis intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Injection: Additional contraindications: Prolonged (&gt;72 hours) prevention or management of preterm labor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral: Additional contraindications: Prevention or treatment of preterm labor",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: When used as a bronchodilator, optimize anti-inflammatory treatment before initiating maintenance treatment with terbutaline. Do not use as a component of chronic therapy without an anti-inflammatory agent. Only the mildest form of asthma (Step 1 and/or exercise-induced) would not require concurrent use based upon asthma guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preterm labor:",
"     <b>",
"      [U.S. Boxed Warning]: Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (&gt;48-72 hours). Use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate.",
"     </b>",
"     Oral terbutaline is contraindicated for acute or chronic use in the management of preterm labor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause CNS stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Terbutaline crosses the placenta; umbilical cord concentrations are ~11% to 48% of maternal blood levels.",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     : Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (&gt;48-72 hours). Use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate. Terbutaline has been used in the management of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13763352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Terbutaline is excreted in breast milk; concentrations are similar to or higher than those in the maternal plasma. Based on information from four cases, exposure to the breast-fed infant would be &lt;1% of the weight-adjusted maternal dose. Adverse events were not observed in nursing infants (Bor&eacute;us, 1982; L&ouml;nnerholm, 1982).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Terbutaline Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Terbutaline Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $43.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $62.21",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, glucose; intake/output; heart rate, blood pressure, respiratory rate; chest pain, shortness of breath; monitor for signs and symptoms of pulmonary edema (when used as a tocolytic); monitor FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests (when used as bronchodilator)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alloxygen (PH);",
"     </li>",
"     <li>",
"      Asmalin (SG);",
"     </li>",
"     <li>",
"      Asthmasian (TH);",
"     </li>",
"     <li>",
"      Ataline (MY);",
"     </li>",
"     <li>",
"      Beta-2 (KP);",
"     </li>",
"     <li>",
"      Bricalin (IL);",
"     </li>",
"     <li>",
"      Bricanil (VE);",
"     </li>",
"     <li>",
"      Bricanyl (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CY, CZ, DK, EG, ET, FI, FR, GB, GH, GM, GN, GY, HK, HN, HU, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Bricanyl retard (NL);",
"     </li>",
"     <li>",
"      Bricanyl Turbuhaler (HU, PL);",
"     </li>",
"     <li>",
"      Britaline (MY);",
"     </li>",
"     <li>",
"      Bronchodam (PH);",
"     </li>",
"     <li>",
"      Bronco Asmo (TH);",
"     </li>",
"     <li>",
"      Bronconyl (TH);",
"     </li>",
"     <li>",
"      Brondyl (TW);",
"     </li>",
"     <li>",
"      Brothine (TW);",
"     </li>",
"     <li>",
"      Bucanil (MY);",
"     </li>",
"     <li>",
"      Bucaril (TH);",
"     </li>",
"     <li>",
"      Butaline (MY);",
"     </li>",
"     <li>",
"      Contimit (DE);",
"     </li>",
"     <li>",
"      Draconyl (GR);",
"     </li>",
"     <li>",
"      Getran (TW);",
"     </li>",
"     <li>",
"      Glin (TW);",
"     </li>",
"     <li>",
"      Nairet (ID);",
"     </li>",
"     <li>",
"      Pulmoxel (PH);",
"     </li>",
"     <li>",
"      Relivan (ID);",
"     </li>",
"     <li>",
"      Terbasmin (ES, IT);",
"     </li>",
"     <li>",
"      Terbu Expectorant (TH);",
"     </li>",
"     <li>",
"      Terbul (LU);",
"     </li>",
"     <li>",
"      Terbulin (IL);",
"     </li>",
"     <li>",
"      Terburop (CO, EC);",
"     </li>",
"     <li>",
"      Terbutalin AL (HU);",
"     </li>",
"     <li>",
"      Terbutalin Stada (PL);",
"     </li>",
"     <li>",
"      Tismalin (ID);",
"     </li>",
"     <li>",
"      Yarisma (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial and uterine smooth muscle by action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with less effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 30-45 minutes; SubQ: 6-15 minute; Inhalation: 5 minutes (maximum effect: 15-60 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Inhalation: 4-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to inactive sulfate conjugates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ doses are more bioavailable than oral",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 11-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 127: &ldquo;Management of Preterm Labor,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2012, 119(6):1308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/22617615/pubmed\" id=\"22617615\" target=\"_blank\">",
"        22617615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 109, 176.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berkman ND, Thorp JM Jr, Hartmann KE, et al, \"Management of Preterm Labor,\" Evidence Report/Technology Assessment No. 18 (Prepared by Research Triangle Institute under Contract No. 290-97-0011). AHRQ Publication No. 01-E021. Rockville (MD) Agency for Healthcare Research and Quality. December 2000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/11127122/pubmed\" id=\"11127122\" target=\"_blank\">",
"        11127122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bohn D, Kalloghlian A, Jenkins J, et al, &ldquo;Intravenous Salbutamol in the Treatment of Status Asthmaticus in Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1984, 12(10):892-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/6435957/pubmed\" id=\"6435957\" target=\"_blank\">",
"        6435957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bor&eacute;us LO and de Ch&acirc;teau PU, \"Terbutaline in Breast Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1982, 13(5):731-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/7082542/pubmed\" id=\"7082542\" target=\"_blank\">",
"        7082542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canny GJ and Levison H, &ldquo;Aerosols - Therapeutic Use and Delivery in Childhood Asthma,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1988, 60(1):11-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/3276242/pubmed\" id=\"3276242\" target=\"_blank\">",
"        3276242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuglsang G, Pedersen S, and Borgstrom L, &ldquo;Dose-Response Relationships of I.V. Administered Terbutaline in Children With Asthma,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(2):315-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/2915294/pubmed\" id=\"2915294\" target=\"_blank\">",
"        2915294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldenhersh N and Rachelefsky GS, &ldquo;Childhood Asthma: Management,&rdquo;",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 1989, 10(9):259-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/2652119/pubmed\" id=\"2652119\" target=\"_blank\">",
"        2652119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guinn DA, Goepfert AR, Owen J, et al, &ldquo;Terbutaline Pump Maintenance Therapy for Prevention of Preterm Delivery: A Double-Blind Trial,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1998, 179(4):874-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/9790362/pubmed\" id=\"9790362\" target=\"_blank\">",
"        9790362",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hearne AE and Nagey DA, \"Therapeutic Agents in Preterm Labor: Tocolytic Agents,\"",
"      <i>",
"       Clin Obstet Gynecol",
"      </i>",
"      2000, 43(4):787-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/11100296/pubmed\" id=\"11100296\" target=\"_blank\">",
"        11100296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly HW, McWilliams BC, Katz R, et al, &ldquo;Safety of Frequent High Dose Nebulized Terbutaline in Children With Acute Severe Asthma,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1990, 64(2 Pt 2):229-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/2301784/pubmed\" id=\"2301784\" target=\"_blank\">",
"        2301784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam F, Gill P, Smith M, et al, &ldquo;Use of the Subcutaneous Terbutaline Pump for Long-Term Tocolysis,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1998, 72(5):810-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      L&ouml;nnerholm G and Lindstr&ouml;m B, \"Terbutaline Excretion Into Breast Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1982, 13(5):729-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/7082541/pubmed\" id=\"7082541\" target=\"_blank\">",
"        7082541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1985, 76(3):409-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/2863296/pubmed\" id=\"2863296\" target=\"_blank\">",
"        2863296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simhav HN and Caritis SN, &ldquo;Prevention of Preterm Delivery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(5):477-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/17671256/pubmed\" id=\"17671256\" target=\"_blank\">",
"        17671256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tipton WR and Nelson HS, &ldquo;Frequent Parenteral Terbutaline in the Treatment of Status Asthmaticus in Children,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1987, 58(4):252-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/3565860/pubmed\" id=\"3565860\" target=\"_blank\">",
"        3565860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Travis BE and McCullough JM, &ldquo;Pharmacotherapy of Preterm Labor,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(1):28-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/8437965/pubmed\" id=\"8437965\" target=\"_blank\">",
"        8437965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zehner WJ Jr, Scott JM, Iannolo PM, et al, &ldquo;Terbutaline vs Albuterol for Out-of-Hospital Respiratory Distress: Randomized Double-Blind Trial,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2(8):686-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/55/12151/abstract-text/7584746/pubmed\" id=\"7584746\" target=\"_blank\">",
"        7584746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9977 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12151=[""].join("\n");
var outline_f11_55_12151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14640925\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225677\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225725\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225681\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225702\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225682\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225683\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245730\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225654\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950984\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225639\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225657\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225732\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225655\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225721\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225734\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225723\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225661\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225643\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300114\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225648\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225673\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225650\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206279\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225688\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763352\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225663\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225652\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038836\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225642\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225660\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/42/26277?source=related_link\">",
"      Terbutaline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=related_link\">",
"      Terbutaline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_55_12152="Endoscopic management of complications from laparoscopic cholecystectomy";
var content_f11_55_12152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic management of complications from laparoscopic cholecystectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12152/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12152/contributors\">",
"     Michael K Sanders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12152/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12152/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12152/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12152/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/55/12152/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic injury to the biliary tree is a well-documented complication of cholecystectomy. This topic review will focus on the role of the endoscopist in the management of these disorders. It is important to appreciate that several injuries, particularly complex hilar lesions or total transections, are usually not amenable to endoscopic treatment. An overview of the complication of laparoscopic cholecystectomy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of laparoscopic cholecystectomy and its sudden and widespread implementation in the early 1990s led to a dramatic increase in the frequency of biliary injury. With increasing experience, the incidence of this complication has declined substantially (from 2.2 percent in a report from 1991 to an overall incidence of 0.6 percent from several more recent series) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the incidence has probably reached a plateau. This was illustrated in a report from a high-volume tertiary referral center, in which the frequency and distribution of bile duct injuries detected by ERCP over a nine-year period (from 1994 to 2003) remained unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/4\">",
"     4",
"    </a>",
"    ]. The actual incidence of biliary injuries may be higher than the above estimates since not all series classified bile leaks that did not require operative management as a complication.",
"   </p>",
"   <p>",
"    Successful management of bile duct injury requires a multidisciplinary team approach incorporating experienced biliary endoscopists, interventional radiologists, and hepatobiliary surgeons. The approach to the patient depends upon the nature and extent of the injury, the presence or absence of biloma, and the timing of discovery. Debate continues within the surgical literature as to whether routine intraoperative cholangiography reduces the risk of biliary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A general classification of biliary injuries has been proposed although it is not universally accepted (",
"    <a class=\"graphic graphic_figure graphicRef66356 \" href=\"UTD.htm?26/2/26662\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the endoscopist, post cholecystectomy biliary tract injuries can be broadly divided into two groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bile leak without significant ductal injury",
"     </li>",
"     <li>",
"      Major ductal injury with or without bile leak",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BILE LEAK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor and clinically insignificant or inapparent bile leaks are common after cholecystectomy. They generally result from ducts in the gallbladder bed (called \"subvesical\" ducts) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Routine postoperative ultrasonography will detect small collections within the gallbladder bed in up to 24 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/10\">",
"     10",
"    </a>",
"    ]. The majority of these resolve without intervention or adverse sequelae.",
"   </p>",
"   <p>",
"    Significant postoperative bile leaks occur in approximately 0.8 to 1.1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Technical problems or intraoperative complications have been reported in up to 50 percent of patients who subsequently develop a biliary tract fistula or injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bile leaks usually present within the first postoperative week, although presentation may be delayed for up to 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/14\">",
"     14",
"    </a>",
"    ]. As mentioned above, minor bile duct leaks, such as those coming from the end of the cystic duct stump or from a duct of Luschka, are associated with low output through a surgical drain and usually resolve without intervention. In contrast, the presence of a significant bile leak is heralded by a persistent bile discharge from an operatively placed drain or T tube tract, or symptoms of pain and fever in association with varying degrees of abdominal distension, ileus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jaundice.",
"   </p>",
"   <p>",
"    The diagnosis can usually be confirmed with an ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/13\">",
"     13",
"    </a>",
"    ]. However, negative imaging (both ultrasonography and computed tomography) does not preclude the possibility of a clinically significant leak. If symptoms continue and the clinical suspicion is strong, cholangiography should be performed.",
"   </p>",
"   <p>",
"    Endoscopic cholangiography can delineate the site of the leak in over 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, it can detect the presence of stones, strictures, and the location of a T-tube (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77959 graphicRef66681 graphicRef67568 \" href=\"UTD.htm?7/48/7943\">",
"     image 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bile leaks can be classified into two groups based upon their cholangiographic magnitude:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High grade leaks demonstrate rapid extravasation of contrast from the biliary tree upon initial injection, at which time negligible intrahepatic filling has occurred (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58317 graphicRef70108 \" href=\"UTD.htm?4/57/5011\">",
"       image 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Low grade leaks require complete or near complete intrahepatic filling to demonstrate contrast extravasation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72621 \" href=\"UTD.htm?22/17/22815\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The table summarizes clinical and cholangiographic data from large series of patients (n &gt;50) with postcholecystectomy bile leaks managed endoscopically (",
"    <a class=\"graphic graphic_table graphicRef71758 \" href=\"UTD.htm?25/27/26044\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/12,15-19\">",
"     12,15-19",
"    </a>",
"    ]. The early reports include patients from the open cholecystectomy era. The cystic duct remnant was the site of bile extravasation in approximately three quarters of patients, while ducts within the gallbladder bed were the source in 6 to 17 percent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80167 \" href=\"UTD.htm?26/4/26703\">",
"     image 4",
"    </a>",
"    ) and common bile duct, common hepatic duct, and T tube tracts accounted for the remainder. Cystic duct leaks occur due to varying combinations of clip dysfunction or misplacement and necrosis or tearing of the cystic duct remnant proximal to the clip. Retained common bile duct stones were detected in 20 to 25 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of endoscopic therapy is to eliminate the transpapillary pressure gradient, thereby permitting preferential transpapillary bile flow rather than extravasation at the site of the leak.",
"   </p>",
"   <p>",
"    The least invasive endoscopic approach possible should be used, which in most patients involves placement of a transpapillary stent without sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/20\">",
"     20",
"    </a>",
"    ]. Although some authors advocate biliary sphincterotomy alone for treatment of low grade leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/21\">",
"     21",
"    </a>",
"    ], it is generally desirable to preserve the biliary sphincter whenever possible, particularly in younger patients. It is usually not necessary to place a stent beyond the site of the leak although in clinical practice this is often done due to its technical simplicity. We prefer 7 rather than 10 French stents if a sphincterotomy is not performed due to the theoretically lower risk of post-ERCP pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .) The majority of patients will be managed effectively by this approach.",
"   </p>",
"   <p>",
"    In the presence of a retained common bile duct stone, a biliary sphincterotomy is usually necessary. Although low grade leaks occurring in the presence of a retained stone can usually be managed by sphincterotomy and stone extraction alone, patients with high grade leaks will likely require a biliary endoprosthesis since sphincterotomy alone does not always completely eliminate the transpapillary pressure gradient.",
"   </p>",
"   <p>",
"    Typically, the stent is left in place for approximately four to six weeks. If a percutaneous drain is in place, the drainage should be less than 10 cc per day prior to removing the stent. In patients without a percutaneous drain, the stent should only be removed once the patient appears well clinically (eg, absence of pain, fever, jaundice, and abdominal distension).",
"   </p>",
"   <p>",
"    An alternative approach in sicker inpatients is to combine sphincterotomy with temporary nasobiliary drainage. This technique produces rapid, reliable decompression and a complete diversion of bile flow due to siphoning of the intrahepatic bile flow [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/22\">",
"     22",
"    </a>",
"    ]. The sealing of the leak can be confirmed by subsequent cholangiogram via the indwelling nasobiliary tube, often in as little as 24 hours, and the tube can be removed prior to discharge. This technique avoids subsequent repeat endoscopy for stent removal. The disadvantages include patient discomfort and the need for continued hospitalization until the drain is ready for removal.",
"   </p>",
"   <p>",
"    There are occasional patients with bile leaks who do not respond to sphincterotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plastic stent placement. Some reports have described that up to 10 percent of patients with bile leaks did not respond to initial endoscopic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/18\">",
"     18",
"    </a>",
"    ]. A case series suggested that such patients can be managed successfully by temporary placement of a covered, self-expanding metal stent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/23\">",
"     23",
"    </a>",
"    ]. In another report, n-butyl-2 cyanoacrylate, a tissue glue monomer, was successfully used in seven of nine patients with refractory bile leaks, thus obviating the need for surgical reintervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approaching apparently refractory bile leaks, the endoscopist must consider the possibility that the leak is coming from transection of an anomalous hepatic duct. This occurs most commonly because of an aberrant right hepatic duct from which the cystic duct arose (",
"    <a class=\"graphic graphic_figure graphicRef66356 \" href=\"UTD.htm?26/2/26662\">",
"     figure 1",
"    </a>",
"    ). Leakage is thus from both the distal aspect of what appears to be the cystic duct and the transected right duct branch. Balloon occlusion cholangiography at repeat ERCP may suggest the diagnosis probability. Confirmation may require MRCP, repeat CT scanning, and at times percutaneous transhepatic cholangiography. Once recognized, these bile leaks often require surgical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of laparoscopic cholecystectomy\", section on 'Diagnosis and management of biliary injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile leaks usually resolve quickly after placement of a stent. However, placement of a stent will not aid in the reabsorption of an established biloma. As a result, approximately one quarter of patients undergo percutaneous drainage of collections after ERCP. As a general rule, collections remaining symptomatic after successful closure of the leak are better managed with percutaneous drainage. Rapid reabsorption can be expected in most cases, even with large collections. A small percentage of patients (4 to 6 percent) require open surgical drainage for loculated collections. As an alternative, EUS-guided successful treatment by creation of an enteral-biloma fistula has been described in report of five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/25\">",
"     25",
"    </a>",
"    ]. Although unproven, it is likely that a delay in referral for endoscopic management may increase the necessity for percutaneous or surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term placement of a biliary stent is definitive therapy for the vast majority of bile leaks that occur in the absence of additional biliary tract injury (",
"    <a class=\"graphic graphic_table graphicRef65102 \" href=\"UTD.htm?32/54/33644\">",
"     table 2",
"    </a>",
"    ). A sudden reduction in bile output is usually evident on the first day following the procedure in patients with a previously placed percutaneous drain. In those without complications, stents can be removed without further cholangiography after four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/26\">",
"     26",
"    </a>",
"    ]. When surgery is necessary it is usually undertaken to drain loculated collections rather than repair defects in the continuity of the biliary tree. Arguably, such an intervention may be avoided by early referral for endoscopic treatment. Complications arising from endoscopic intervention are minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAJOR BILIARY TRACT INJURY WITH OR WITHOUT BILE LEAK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile duct injuries are identified intraoperatively in up to one quarter of patients, although recognition of injury appears to be less frequent during laparoscopic compared to open cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. Many of these injuries can be repaired immediately after recognition; some of these patients will subsequently require endoscopic evaluation or intervention.",
"   </p>",
"   <p>",
"    For patients with an unrecognized injury, the nature and timing of clinical presentation is variable and primarily influenced by the type of injury. The coexistence of a bile leak (from major duct disruption or complete transection) usually portends an early presentation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60875 graphicRef68567 \" href=\"UTD.htm?34/40/35458\">",
"     image 5A-B",
"    </a>",
"    ). In a series of 53 patients, for example, those with a bile leak presented at a median of three days. In contrast, patients who had developed strictures without bile leak had a significantly longer symptom free interval and presented at a median of 57 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/13\">",
"     13",
"    </a>",
"    ]. The latter patients usually had signs of biliary obstruction (jaundice, cholestatic liver function tests, biliary dilatation on ultrasound). These features were usually absent in patients with a bile leak alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Approach to the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of sepsis or peritonitis, the clinical status of the patient with an unrecognized biliary tract injury can deteriorate rapidly. Thus early diagnosis is imperative and imaging should not be delayed if doubt exists. Ultrasonography will detect collections or biliary dilatation. Cholescintigraphy (HIDA scan) is useful for detecting biliary leaks. CT scanning may also be necessary.",
"   </p>",
"   <p>",
"    In practice, patients usually have had an ultrasound and CT scan before the endoscopist has been consulted. Cholangiography is performed to define biliary anatomy. ERCP is preferred to percutaneous transhepatic cholangiography (PTC) due to its lower incidence of complications and because it does not require an indwelling percutaneous drain with the attendant risks of bile leak and sepsis. For similar reasons, magnetic resonance cholangiopancreatography (MRCP) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70654 \" href=\"UTD.htm?0/43/688\">",
"     image 6",
"    </a>",
"    ) may be preferred to PTC (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69335 graphicRef56602 \" href=\"UTD.htm?5/9/5268\">",
"     image 7A-B",
"    </a>",
"    ) in patients in whom complete biliary transection precludes ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bile duct injuries have traditionally been seen as the purview of the surgeon, with the biliary endoscopist having a limited role. Controversy continues to exist over the optimal therapeutic algorithm since both methods can be effective and because there have been no large prospective controlled trials comparing surgery with endoscopic management [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/28\">",
"     28",
"    </a>",
"    ]. Such a trial is unlikely to be conducted due to the relative infrequency of the condition, the lack of concentration of such patients within specialist centers, and the heterogeneous nature of the lesions to be dealt with.",
"   </p>",
"   <p>",
"    In a retrospective report from the Amsterdam group, the outcome of endoscopic therapy was compared to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/27\">",
"     27",
"    </a>",
"    ]. This study summarizes the total experience in the management of benign biliary strictures within this unit between 1981 and 1990. Thirty-five patients were selected for surgical management and 66 were managed endoscopically. Patient characteristics, type of initial injury, and level of obstruction were comparable between the two groups, although within the endoscopic group there was a greater proportion of Bismuth type 1 lesions (45 versus 29 percent) and a lesser frequency of Bismuth type 4 lesions (11 versus 20 percent) (",
"    <a class=\"graphic graphic_figure graphicRef66356 \" href=\"UTD.htm?26/2/26662\">",
"     figure 1",
"    </a>",
"    ). However, the difference was not significant. After a mean follow-up of 50 months in the surgical group and 42 months in the endoscopic group an excellent (asymptomatic with normal or stable liver function tests) or good (only one episode of cholangitis) response was achieved in 83 percent of patients in both groups.",
"   </p>",
"   <p>",
"    There was a significant difference in the early complication rate (26 versus 8 percent) in favor of endoscopy. During the endoscopic treatment protocol (three monthly stent exchanges over 12 months) 21 percent of patients had at least one episode of cholangitis related to stent occlusion. This responded readily to stent exchange in all cases. Surgery involved a biliodigestive anastomosis in all cases (usually a proximal hepatico-jejunostomy with Roux-en-Y jejunal loop). Six patients (17 percent) developed recurrent biliary strictures requiring further surgery at postoperative intervals between 22 and 81 months.",
"   </p>",
"   <p>",
"    Similar results have been described in other surgical series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/13,29,30\">",
"     13,29,30",
"    </a>",
"    ]. One group reported a multicenter experience in 49 patients during the introduction of laparoscopic cholecystectomy in the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/29\">",
"     29",
"    </a>",
"    ]. Three patients died due to a delay in establishing the diagnosis. Twelve patients (25 percent) developed biliary strictures postoperatively at intervals ranging between two weeks and nine months during a relatively short overall follow-up period.",
"   </p>",
"   <p>",
"    Another series included 81 patients with post laparoscopic cholecystectomy biliary tract injury at three tertiary referral institutions within the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/30\">",
"     30",
"    </a>",
"    ]. Sixteen of 17 patients who had biliary enteric bypass performed soon after the initial injury at the referring institution required additional intervention for anastomotic strictures or stenosis.",
"   </p>",
"   <p>",
"    In another report, surgery performed in the early postoperative phase was associated with an 80 percent complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/13\">",
"     13",
"    </a>",
"    ]. In comparison, surgery delayed 8 to 12 weeks to allow local inflammatory reactions to settle was attended by only a 17 percent complication rate.",
"   </p>",
"   <p>",
"    From these and other published data some reasonable conclusions can be drawn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major biliary tract injuries are best managed in a tertiary referral center with particular expertise in this field.",
"     </li>",
"     <li>",
"      A cooperative multidisciplinary approach is required.",
"     </li>",
"     <li>",
"      The success of endoscopic therapy depends upon the type of injury.",
"     </li>",
"     <li>",
"      Surgery performed in the early postoperative phase in the absence of biliary dilatation and the presence of an acute local inflammatory response with or without ileus or sepsis is likely to ultimately fail. Endoscopic therapy is preferable at this stage. It will establish the diagnosis and may obviate the need for surgery.",
"     </li>",
"     <li>",
"      An attempt at endoscopic therapy does not preclude subsequent surgical intervention but the converse is not always true. Endoscopic stenting should be seen as a possible definitive therapy and at the very least a bridge to surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Endoscopic therapy for strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several variations in stenting protocols have been described in the medical literature. As for other benign biliary strictures, the technique involves serial incremental biliary dilatation with successive placement of endoprostheses side by side [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/31\">",
"     31",
"    </a>",
"    ]. Sphincterotomy is usually performed due to the necessity for repeated stent exchanges and side by side stent placement. Endoscopic therapy will usually not succeed in patients who have complete transection of the bile duct, since a guidewire cannot be passed across the lesion into the biliary tree above, although successful stenting has been described in such a patient in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/32\">",
"     32",
"    </a>",
"    ]. In an additional case, a combined percutaneous-endoscopic approach has been described in the repair of a transected hepatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal number, size, endpoints, and frequency of replacement of stents has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/13,27,34-38\">",
"     13,27,34-38",
"    </a>",
"    ]. The following two examples illustrate two approaches that have been described in the largest series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stenting protocol reported in the most recent series from the Amsterdam group (74 patients) involved placement of two 10 F stents (whenever possible), which were exchanged every three months for a total of 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/39\">",
"       39",
"      </a>",
"      ]. Dilation was required in approximately 25 percent of patients before stent insertion. Percutaneous cholangiography was required in three patients. The stents were removed if the stricture was judged subjectively to be dilated (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51984 graphicRef75529 graphicRef62781 \" href=\"UTD.htm?30/38/31334\">",
"       image 8A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The stenting protocol described in a group from Rome (42 patients) involved placing as many stents as possible during each session [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/38\">",
"       38",
"      </a>",
"      ]. Polyethylene straight 10F stents were preferred. Dilation was performed as needed. Percutaneous transhepatic cholangiography with placement of a guidewire was required in three patients. Long-term follow-up was available for 35 of the patients, with a mean follow-up of 13.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/40\">",
"       40",
"      </a>",
"      ]. Recurrent acute cholangitis occurred in seven patients (20 percent) after a mean of 6.8 years. Four of the patients with cholangitis had postoperative biliary stricture recurrences and were treated with stent placement. The remaining three patients had common bile duct stones that were extracted. No additional recurrences were reported in the seven patients after a mean follow-up of an additional 7.1 years. The other 28 patients remained asymptomatic with no reports of abnormal liver tests or abdominal ultrasound results throughout follow-up.",
"      <br/>",
"      <br/>",
"      Patients were scheduled to return for elective stent exchange every three months. At each exchange the number of stents was increased to the maximum permitted by the diameter of the duct distal to the stricture and the diameter of the stricture itself. The mean number of stents inserted ranged from 1 to 4 (mean 1.7) during the initial session to 1 to 6 (mean 3.2) during the last procedure. The treatment protocol was stopped when complete disappearance of the stricture was demonstrated by occlusion cholangiography immediately following stent removal and confirmed by cholangiography through a nasobiliary tube 24 to 48 hours after stent removal. Patients were then followed by clinical evaluation, liver function tests and transabdominal ultrasound after one month, then every three months during the first year and then every six months thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least one group has described successful balloon dilation of strictures in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/36\">",
"     36",
"    </a>",
"    ]. However, balloon dilation used as monotherapy is unlikely to be successful in the long term, since the relatively transient nature of its effect is insufficient to overcome the ongoing fibro-inflammatory response associated with significant biliary injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the published series suggest that endoscopic therapy is ultimately successful in approximately 50 to 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/41\">",
"     41",
"    </a>",
"    ]. Outcomes from the largest two series discussed above illustrate the range of observations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the most recent series from the Amsterdam group [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/39\">",
"       39",
"      </a>",
"      ], stent placement was successful in 80 percent of patients. Only 44 patients (59 percent of the original cohort and 75 percent of those who had successful initial stent placement) completed 12 months of stent treatment. Fifteen patients dropped out due to noncompliance (10 patients), death (three patients), or need for surgery (two patients).",
"      <br/>",
"      <br/>",
"      Recurrent stenosis developed in 9 of the 44 patients (20 percent) after a median follow-up of 9.1 years. Recurrent strictures were observed from two months to 15 years after stent removal (median 2.6 months). All but one of the patients presented within six months. Thus, 47 percent of the original cohort were stricture free on long-term follow-up.",
"      <br/>",
"      <br/>",
"      There were a total of 20 deaths (27 percent) during the follow-up period, eight of which appeared to be related to biliary diseases, and five of which were related to ERCP. This suggests an approximate procedure-related mortality rate of 2 to 3 percent and a complication rate of 10 to 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/41\">",
"       41",
"      </a>",
"      ]. Major complications included cholangitis, pancreatitis, bleeding, and stent migration requiring surgery. Complications were much more likely in patients who were noncompliant with the stent exchange protocol. The complication rate was comparable to that observed in surgical series and emphasizes the difficulty in treating postoperative strictures. This study also suggests that an endoscopic approach may not be suitable in patients who cannot commit to the rigorous ERCP protocol described above.",
"     </li>",
"     <li>",
"      Long-term follow-up (mean 49 months) was possible in 44 of the original 55 patients (76 percent) included in the series from Rome [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/38\">",
"       38",
"      </a>",
"      ]. The other patients were not eligible for the stenting protocol due to complete transection of the bile duct (five patients), placement of a metal stent (five patients), death during stent placement (one patient), the need for surgery (one patient), and loss to follow-up (one patient). Complications included cholangitis (10 patients), pancreatitis (one patient), recurrent jaundice (one patient), and stent migration (five patients, including one who developed duodenal perforation). Two patients died of unrelated causes.",
"      <br/>",
"      <br/>",
"      No patient developed clinically significant recurrent strictures. While the follow-up period was shorter than described in Amsterdam group, it was sufficiently long to have revealed the majority of recurrences. Whether the better results can be attributed to the differences in the treatment protocol is unclear. Other possible contributing factors may have been a higher rate of patient compliance in the report from Rome, and other individual patient characteristics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experience in other reports has been similar to that described above. As an example, a preliminary report from a group in Toronto included 21 patients who were followed for a mean of 9.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12152/abstract/37\">",
"     37",
"    </a>",
"    ]. An excellent or good response was sustained in 81 percent of patients. Delay in intervention beyond three months after the initial biliary injury appeared to predispose to a less favorable response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic therapy is successful in about 90 percent of patients with a postcholecystectomy biliary leak when success is defined as resolution without the need for further surgery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bile leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of endoscopic therapy in patients with a postcholecystectomy biliary leak is to eliminate the transpapillary pressure gradient, thereby permitting preferential transpapillary bile flow rather than extravasation at the site of the leak. We suggest using the least invasive endoscopic approach possible, which in most patients involves placement of a transpapillary stent without sphincterotomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bile leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The results of endoscopic therapy for major biliary tract injury (excluding disconnection) for selected patients are at least comparable to those of surgery. The two approaches should be seen as complementary. Because of potential complications and technical issues, endoscopic therapy should be performed in centers with highly experienced endoscopists. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Major biliary tract injury with or without bile leak'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/1\">",
"      A prospective analysis of 1518 laparoscopic cholecystectomies. The Southern Surgeons Club. N Engl J Med 1991; 324:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/2\">",
"      Deziel DJ, Millikan KW, Economou SG, et al. Complications of laparoscopic cholecystectomy: a national survey of 4,292 hospitals and an analysis of 77,604 cases. Am J Surg 1993; 165:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/3\">",
"      McMahon AJ, Fullarton G, Baxter JN, O'Dwyer PJ. Bile duct injury and bile leakage in laparoscopic cholecystectomy. Br J Surg 1995; 82:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/4\">",
"      Khan MH, Howard TJ, Fogel EL, et al. Frequency of biliary complications after laparoscopic cholecystectomy detected by ERCP: experience at a large tertiary referral center. Gastrointest Endosc 2007; 65:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/5\">",
"      Kullman E, Borch K, Lindstr&ouml;m E, et al. Value of routine intraoperative cholangiography in detecting aberrant bile ducts and bile duct injuries during laparoscopic cholecystectomy. Br J Surg 1996; 83:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/6\">",
"      Wright KD, Wellwood JM. Bile duct injury during laparoscopic cholecystectomy without operative cholangiography. Br J Surg 1998; 85:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/7\">",
"      Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 1995; 180:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/8\">",
"      Kitami M, Murakami G, Suzuki D, et al. Heterogeneity of subvesical ducts or the ducts of Luschka: a study using drip-infusion cholangiography-computed tomography in patients and cadaver specimens. World J Surg 2005; 29:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/9\">",
"      Ko K, Kamiya J, Nagino M, et al. A study of the subvesical bile duct (duct of Luschka) in resected liver specimens. World J Surg 2006; 30:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/10\">",
"      Elboim CM, Goldman L, Hann L, et al. Significance of post-cholecystectomy subhepatic fluid collections. Ann Surg 1983; 198:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/11\">",
"      Trondsen E, Ruud TE, Nilsen BH, et al. Complications during the introduction of laparoscopic cholecystectomy in Norway. A prospective multicentre study in seven hospitals. Eur J Surg 1994; 160:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/12\">",
"      Barkun AN, Rezieg M, Mehta SN, et al. Postcholecystectomy biliary leaks in the laparoscopic era: risk factors, presentation, and management. McGill Gallstone Treatment Group. Gastrointest Endosc 1997; 45:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/13\">",
"      Bergman JJ, van den Brink GR, Rauws EA, et al. Treatment of bile duct lesions after laparoscopic cholecystectomy. Gut 1996; 38:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/14\">",
"      Davidoff AM, Branum GD, Meyers WC. Clinical features and mechanisms of major laparoscopic biliary injury. Semin Ultrasound CT MR 1993; 14:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/15\">",
"      Bourke MJ, Elfant AB, Alhalel R, et al. Endoscopic management of postoperative bile leak in 85 patients. Gastrointest Endosc 1995; 41:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/16\">",
"      Liguory C, Vitale GC, Lefebre JF, et al. Endoscopic treatment of postoperative biliary fistulae. Surgery 1991; 110:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/17\">",
"      Davids PH, Rauws EA, Tytgat GN, Huibregtse K. Postoperative bile leakage: endoscopic management. Gut 1992; 33:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/18\">",
"      Ryan ME, Geenen JE, Lehman GA, et al. Endoscopic intervention for biliary leaks after laparoscopic cholecystectomy: a multicenter review. Gastrointest Endosc 1998; 47:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/19\">",
"      Hourigan LF, Bourke MJ, Williams SJ. Endoscopic management of postoperative bile leak in 53 patients (abstract). J Gastroenterol Hepatol 1999; 14:A145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/20\">",
"      Kaffes AJ, Hourigan L, De Luca N, et al. Impact of endoscopic intervention in 100 patients with suspected postcholecystectomy bile leak. Gastrointest Endosc 2005; 61:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/21\">",
"      Sandha GS, Bourke MJ, Haber GB, Kortan PP. Endoscopic therapy for bile leak based on a new classification: results in 207 patients. Gastrointest Endosc 2004; 60:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/22\">",
"      Chow S, Bosco JJ, Heiss FW, et al. Successful treatment of post-cholecystectomy bile leaks using nasobiliary tube drainage and sphincterotomy. Am J Gastroenterol 1997; 92:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/23\">",
"      Kahaleh M, Sundaram V, Condron SL, et al. Temporary placement of covered self-expandable metallic stents in patients with biliary leak: midterm evaluation of a pilot study. Gastrointest Endosc 2007; 66:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/24\">",
"      Seewald S, Groth S, Sriram PV, et al. Endoscopic treatment of biliary leakage with n-butyl-2 cyanoacrylate. Gastrointest Endosc 2002; 56:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/25\">",
"      Shami VM, Talreja JP, Mahajan A, et al. EUS-guided drainage of bilomas: a new alternative? Gastrointest Endosc 2008; 67:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/26\">",
"      Coelho-Prabhu N, Baron TH. Assessment of need for repeat ERCP during biliary stent removal after clinical resolution of postcholecystectomy bile leak. Am J Gastroenterol 2010; 105:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/27\">",
"      Davids PH, Tanka AK, Rauws EA, et al. Benign biliary strictures. Surgery or endoscopy? Ann Surg 1993; 217:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/28\">",
"      Lillemoe KD, Melton GB, Cameron JL, et al. Postoperative bile duct strictures: management and outcome in the 1990s. Ann Surg 2000; 232:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/29\">",
"      Schol FP, Go PM, Gouma DJ. Outcome of 49 repairs of bile duct injuries after laparoscopic cholecystectomy. World J Surg 1995; 19:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/30\">",
"      Woods MS, Traverso LW, Kozarek RA, et al. Characteristics of biliary tract complications during laparoscopic cholecystectomy: a multi-institutional study. Am J Surg 1994; 167:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/31\">",
"      Bourke MJ, Elfant AB, Alhalel R, et al. Sphincterotomy-associated biliary strictures: features and endoscopic management. Gastrointest Endosc 2000; 52:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/32\">",
"      Baron TH, Feitoza AB, Nagorney DM. Successful endoscopic treatment of a complete transection of the bile duct complicating laparoscopic cholecystectomy. Gastrointest Endosc 2003; 57:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/33\">",
"      Dumonceau JM, Baize M, Devi&egrave;re J. Endoscopic transhepatic repair of the common hepatic duct after excision during cholecystectomy. Gastrointest Endosc 2000; 52:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/34\">",
"      Berkelhammer C, Kortan P, Haber GB. Endoscopic biliary prostheses as treatment for benign postoperative bile duct strictures. Gastrointest Endosc 1989; 35:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/35\">",
"      Davids PH, Rauws EA, Coene PP, et al. Endoscopic stenting for post-operative biliary strictures. Gastrointest Endosc 1992; 38:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/36\">",
"      Geenen DJ, Geenen JE, Hogan WJ, et al. Endoscopic therapy for benign bile duct strictures. Gastrointest Endosc 1989; 35:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/37\">",
"      Duvall A, Haber GB, Kortan P, et al. Long term follow up of endoscopic stenting for benign postoperative bile duct strictures (abstract). Gastrointest Endosc 1997; 45:AB129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/38\">",
"      Costamagna G, Pandolfi M, Mutignani M, et al. Long-term results of endoscopic management of postoperative bile duct strictures with increasing numbers of stents. Gastrointest Endosc 2001; 54:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/39\">",
"      Bergman JJ, Burgemeister L, Bruno MJ, et al. Long-term follow-up after biliary stent placement for postoperative bile duct stenosis. Gastrointest Endosc 2001; 54:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/40\">",
"      Costamagna G, Tringali A, Mutignani M, et al. Endotherapy of postoperative biliary strictures with multiple stents: results after more than 10 years of follow-up. Gastrointest Endosc 2010; 72:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12152/abstract/41\">",
"      Lee JG, Leung JW. Long-term follow-up after biliary stent placement for postoperative bile duct stenosis. Gastrointest Endosc 2001; 54:272.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 637 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12152=[""].join("\n");
var outline_f11_55_12152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BILE LEAK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAJOR BILIARY TRACT INJURY WITH OR WITHOUT BILE LEAK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Endoscopic therapy for strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/637|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/18/27951\" title=\"diagnostic image 1A\">",
"      Stone related cystic duct leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/12/39119\" title=\"diagnostic image 1B\">",
"      T tube related bile leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/51/6960\" title=\"diagnostic image 1C\">",
"      Right hepatic radoca bile leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/39/37503\" title=\"diagnostic image 2A\">",
"      High grade cystic duct leak I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/35/8767\" title=\"diagnostic image 2B\">",
"      High grade cystic duct leak II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/17/22815\" title=\"diagnostic image 3\">",
"      Low grade cystic duct leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/4/26703\" title=\"diagnostic image 4\">",
"      Duct of Luschka leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/20/15695\" title=\"diagnostic image 5A\">",
"      Complete CBD transection I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/60/19407\" title=\"diagnostic image 5B\">",
"      Complete CBD transection II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/43/688\" title=\"diagnostic image 6\">",
"      CBD transection MRCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/59/41919\" title=\"diagnostic image 7A\">",
"      PTC before hepaticojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/5/40031\" title=\"diagnostic image 7B\">",
"      PTC after hepaticojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/35/44607\" title=\"diagnostic image 8A\">",
"      Postop CBD stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/21/9567\" title=\"diagnostic image 8B\">",
"      Postop CBD stricture stented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/24/33167\" title=\"diagnostic image 8C\">",
"      Postop CBD stricture resolved",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/637|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/2/26662\" title=\"figure 1\">",
"      Classification of iatrogenic bile duct injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/27/26044\" title=\"table 1\">",
"      Postoperative bile leak studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/54/33644\" title=\"table 2\">",
"      Postoperative bile leak results",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_55_12153="Acute fatty liver Trichrome";
var content_f11_55_12153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Acute fatty liver of pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trichrome stain of a liver biopsy from a patient with acute fatty liver of pregnancy. Left panel: Low power view shows pallor of the hepatocytes surrounding the central vein (CV). Right panel: High power view reveals disruption of the plate pattern with \"dropped out\" hepatocytes, lobular disarray, and vacuolated, pale hepatocytes (microvesicular fat).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Caroline A. Riely, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12153=[""].join("\n");
var outline_f11_55_12153=null;
var title_f11_55_12154="Primary hyperoxaluria";
var content_f11_55_12154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary hyperoxaluria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12154/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12154/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/55/12154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/55/12154/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/55/12154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperoxalurias (PHs) are rare inborn errors of glyoxylate metabolism characterized by the overproduction of oxalate, which is deposited as calcium oxalate in various organs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The kidney is the prime target for oxalate deposition, which leads to end-stage renal disease in a significant number of cases.",
"   </p>",
"   <p>",
"    PH is primarily caused by autosomal recessive enzymatic defects in glyoxylate metabolism that result in enhanced oxalate production.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PH type 1 is due to the defects in the gene that encodes the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT), which is involved in the conversion of glyoxylate to glycine [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/6\">",
"       6",
"      </a>",
"      ]. It accounts for about 80 percent of PH cases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary hyperoxaluria type 1'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      PH type 2 is due to defects in the gene that encodes the cytosolic enzyme glyoxylate",
"      <span class=\"nowrap\">",
"       reductase/hydroxypyruvate",
"      </span>",
"      reductase (GRHPR), which is involved in the conversion of glyoxylate to glycolate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/8\">",
"       8",
"      </a>",
"      ]. It accounts for about 10 percent of PH cases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22971096\">",
"       'Primary hyperoxaluria type 2'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      PH type 3 is due to mutations in the HOGA1 gene that encodes the mitochondrial 4-hydroxy-2-oxoglutarate aldolase enzyme. It appears PH type 3 accounts for about one-half of the remaining 10 percent of patients who do not have either type 1 or 2 disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7,9,10\">",
"       7,9,10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H94201825\">",
"       'Primary hyperoxaluria type 3'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of PH types 1 and 2 are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY HYPEROXALURIA TYPE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although PH type 1 (MIM #259900) is the more common of the three types of PH accounting for about 80 percent of patients with PH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7\">",
"     7",
"    </a>",
"    ], it is a rare disorder with a prevalence of one to three per million in Europe and North America, but appears to be more frequent in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543655503\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In PH type 1, the genetic defect results in decreased or absent activity of the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT), which normally converts glyoxylate to glycine. This inborn error of metabolism leads to an increase in the glyoxylate pool and later overproduction of oxalate.",
"   </p>",
"   <p>",
"    The AGXT gene maps to chromosome 2q36-37 and encodes for a 43 kDa protein [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. More than 150 mutations have been identified in the AGXT gene, which are found in all 11 exons of the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The mutations are predominantly single nucleotide substitutions (75 percent) including missense, nonsense, and splice side mutations, and the remaining mutations are due to deletions and insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These mutations result in three different expressions of AGT protein and its activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of both immunoreactive AGT protein and AGT catalytic activity, which occurs in about 40 percent of patients.",
"     </li>",
"     <li>",
"      Presence of immunoreactive AGT protein and absence of AGT catalytic activity, which occurs in about 15 percent of patients.",
"     </li>",
"     <li>",
"      Presence of both immunoreactive AGT protein and AGT catalytic activity but at levels that are 50 percent below normal values. In these patients, most of the AGT is localized in the mitochondria and not in the peroxisomes (mistargeting phenotype).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study that sequenced the entire AGXT gene in individuals with liver biopsy-proven PH type 1, mutations were detected in 47 of 48 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/18\">",
"     18",
"    </a>",
"    ]. When sequencing data were limited to the three of the 11 exons most frequently affected (1, 4, and 7), molecular analysis was able to detect the genetic defect in 37 of the 48 patients (77 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41563359\">",
"    <span class=\"h3\">",
"     Genotype/phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PH type 1 is a heterogeneous disease with variable expression in patients and even in family members with the same genotype. There has been speculation that environmental factors or modifier genes are responsible for the range of phenotypes within a single pedigree.",
"   </p>",
"   <p>",
"    There appears to be some correlation between genotype and phenotype for specific mutations of the AGXT gene. In particular, urinary oxalate excretion can significantly be reduced in patients with the most common mutation p.Gly170Arg (reported allelic frequency of 21.5 percent in Caucasian patients) by pyridoxine medication resulting in better long-term outcomes, when diagnosis is made early enough for medical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A similar positive response to pyridoxine therapy is also seen in patients with p.Phe152Ile mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H58187731\">",
"     'Medical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41563366\">",
"    <span class=\"h3\">",
"     Oxalate deposition and renal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excess oxalate that is produced in PH is primarily excreted by the kidneys. In patients with PH type 1, urinary oxalate excretion exceeds 1",
"    <span class=\"nowrap\">",
"     mmol/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day (normal &lt;0.5",
"    <span class=\"nowrap\">",
"     mmol/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"     22",
"    </a>",
"    ]. The increased urinary excretion of oxalate results in urinary calcium oxalate supersaturation, which leads to crystal aggregation, urolithiasis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrocalcinosis (",
"    <a class=\"graphic graphic_picture graphicRef65169 \" href=\"UTD.htm?41/19/42302\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50463 \" href=\"UTD.htm?0/45/735\">",
"     image 1",
"    </a>",
"    ). Calcium oxalate crystals are also deposited within the renal interstitium and renal tubule cells (oxalosis). Nephrocalcinosis or recurrent urolithiasis can cause renal parenchymal inflammation and fibrosis and, if persistent, end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"     22",
"    </a>",
"    ]. Other urinary complications associated with urolithiasis, such as infection and obstruction, also contribute to renal damage in affected patients.",
"   </p>",
"   <p>",
"    As the glomerular filtration rate falls below 30 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , plasma oxalate levels increase because of reduced urinary oxalate excretion. When plasma oxalate exceeds 30",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    which is the plasma supersaturation threshold for calcium oxalate, calcium oxalate is deposited into other tissues including the retina, myocardium, vessel walls, skin, bone, and the central nervous system, which leads to the non-renal manifestations of PH. (See",
"    <a class=\"local\" href=\"#H82373131\">",
"     'Systemic oxalosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical and laboratory manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of PH type 1 varies with age and clinical findings because of marked heterogeneity of disease expression. The age range at diagnosis ranges from less than one year of age to over 50 years of age. In a case series of 155 patients from 129 unrelated families, the first symptoms (primarily renal manifestations) occurred before one year of age in 26 percent and after 15 years of age in 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/20\">",
"     20",
"    </a>",
"    ]. In this multicenter European study, there was ethnic heterogeneity including 52 percent of patients of Western European descent, and 43 percent from North Africa and the Middle East. This suggests the prevalence of PH type 1 may be higher in North Africa and the Middle East.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16756187\">",
"    <span class=\"h3\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five clinical presentations of PH type 1 have been described based on the age of presentation and renal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infantile oxalosis (26 percent) &ndash; Infants generally present before six months of age with nephrocalcinosis and renal impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/20,25,26\">",
"       20,25,26",
"      </a>",
"      ]. In a case series of 78 infants, presenting symptoms and findings included nephrocalcinosis (91 percent), failure to thrive (22 percent), urinary tract infection (21 percent), and end-stage renal disease (ESRD, 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/26\">",
"       26",
"      </a>",
"      ]. ESRD developed at a mean age of three years, and, in many cases, was present at the time of diagnosis.",
"     </li>",
"     <li>",
"      Childhood with recurrent urolithiasis and rapid decline in renal function (30 percent) &ndash; In these patients, the first symptoms are those usually associated with urolithiasis (renal colic, hematuria, and urinary tract infection), and, in a few cases, bilateral obstruction with acute renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7,20,27\">",
"       7,20,27",
"      </a>",
"      ]. The calcium oxalate stones formed in patients with PH are bilateral and radiopaque on radiologic examination.",
"     </li>",
"     <li>",
"      Occasional stone formation in adulthood (30 percent).",
"     </li>",
"     <li>",
"      Diagnosis only after failed isolated renal transplantation (10 percent).",
"     </li>",
"     <li>",
"      Diagnosis after family screening (13 percent) &ndash; In the previously discussed case series of 155 patients, 20 were diagnosed after family screening, including three individuals who were asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ESRD develops in approximately one-half of patients by young adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/20,28\">",
"     20,28",
"    </a>",
"    ]. In the above case series, 14 of 22 patients from developing geographic areas (eg, North Africa, Middle East, and Brazil) presented with ESRD at the time of diagnosis. The rapidity of ESRD progression is variable and is dependent on residual enzyme activity and the response to pyridoxine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/29\">",
"     29",
"    </a>",
"    ]. In North America, PH type 1 is responsible for approximately 0.1 percent of cases of chronic kidney disease in children and is the primary diagnosis in 0.5 percent of children who undergo renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41563359\">",
"     'Genotype/phenotype correlation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82373131\">",
"    <span class=\"h3\">",
"     Systemic oxalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the glomerular filtration rate falls below 30 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , the combination of oxalate overproduction and reduced urinary oxalate excretion results in systemic oxalosis with potential calcium oxalate deposition in the heart, blood vessels, joints, bone, and retina [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1,22,31\">",
"     1,22,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41563366\">",
"     'Oxalate deposition and renal injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Deposition in these organs can lead to the following clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac conduction defects that may result in cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Poor peripheral circulation that results in distal gangrene, and difficulties with vascular access for hemodialysis.",
"     </li>",
"     <li>",
"      Bone manifestations that include pain, erythropoietin-resistant anemia, and an increased risk for spontaneous fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/24\">",
"       24",
"      </a>",
"      ]. Oxalate deposition may be seen as dense suprametaphyseal bands on x-rays and are most prominent in the metaphyses of long bones and trabecular bones. Osteoarticular manifestations are severe in patients who have been on dialysis for more than one year.",
"     </li>",
"     <li>",
"      Oxalate deposition in the joints can lead to synovitis with reduced mobility and pain.",
"     </li>",
"     <li>",
"      Oxalate deposition in the retinal epithelium and the macula can cause diminished visual acuity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other findings include hypothyroidism, peripheral neuropathy, dental problems (tooth pain, root resorption, and pulp exposure), and skin manifestations including livedo reticularis, peripheral gangrene, and calcinosis cutis metastatica [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the rarity of PH, a strong clinical suspicion is needed to ensure there is not a delay in the diagnosis, as the efficacy of treatment is dependent on early diagnosis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of PH type 1 is made in the following step-wise approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical diagnosis is suspected based on findings suggestive of PH.",
"     </li>",
"     <li>",
"      Metabolic screening demonstrates markedly increased urinary oxalate excretion. In addition, increased urinary excretion of glycolate is strongly supportive of the diagnosis of PH type 1.",
"     </li>",
"     <li>",
"      The diagnosis of PH type 1 is confirmed by molecular genetic testing that demonstrates a mutation of the alanine:glyoxylate aminotransferase (AGXT) gene.",
"     </li>",
"     <li>",
"      The diagnosis can also be confirmed by a liver biopsy demonstrating absent or significantly reduced AGT activity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the diagnosis is established, further evaluation assesses the function of potentially affected organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82374142\">",
"    <span class=\"h3\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PH should be suspected in children and infants with any of the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1,37-39\">",
"     1,37-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent calcium stones (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50463 \" href=\"UTD.htm?0/45/735\">",
"       image 1",
"      </a>",
"      ), especially in a patient with oxalate crystals in the urine sediment (",
"      <a class=\"graphic graphic_picture graphicRef65169 \" href=\"UTD.htm?41/19/42302\">",
"       picture 1",
"      </a>",
"      ) and normal urinary calcium and uric acid excretion",
"     </li>",
"     <li>",
"      Pure calcium oxalate monohydrate stones (",
"      <a class=\"graphic graphic_picture graphicRef67694 \" href=\"UTD.htm?10/20/10561\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nephrocalcinosis, especially if associated with a decrease in glomerular filtration rate (GFR)",
"     </li>",
"     <li>",
"      Marked hyperoxaluria in the absence of gastrointestinal disease, the ingestion of megadose vitamin C, or increased intake of oxalate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a survey of nephrologists in the United States, a delay in the recognition of PH was noted in over 40 percent of patients (average interval of 3.4 years from time of first symptoms to diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7\">",
"     7",
"    </a>",
"    ]. This delay was due to failure to recognize the possibility of PH as a diagnosis in children with urolithiasis and nephrocalcinosis. The delay in diagnosis resulted in failure to implement intensive medical therapy in a timely manner in a significant number of patients, as 30 percent of the patients had end-stage renal disease (ESRD) at the time of diagnosis. Intensive medical therapy may otherwise have delayed the progression of ESRD in these patients. (See",
"    <a class=\"local\" href=\"#H58187731\">",
"     'Medical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82374149\">",
"    <span class=\"h4\">",
"     Metabolic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis relies on metabolic screening that demonstrates a markedly",
"    <strong>",
"     increased",
"    </strong>",
"    urinary excretion of oxalate (ie, greater than 1",
"    <span class=\"nowrap\">",
"     mmol/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day [90",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day]). Some patients excrete as much as 1.5 to 3",
"    <span class=\"nowrap\">",
"     mmol/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day (135 to 270",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day). Normal urinary oxalate excretion is less than 0.5",
"    <span class=\"nowrap\">",
"     mmol/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day (45",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day).",
"   </p>",
"   <p>",
"    In some patients, obtaining a 24-hour urine collection is difficult, especially in infants and small children who are not toilet trained. As a result, oxalate excretion can be evaluated by measuring the molar oxalate:creatinine ratio in spot urine samples. The",
"    <strong>",
"     normative",
"    </strong>",
"    values for oxalate:creatinine",
"    <span class=\"nowrap\">",
"     (mmol/mmol)",
"    </span>",
"    is age dependent as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22,34\">",
"     22,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants less than 6 months of age: 0.37",
"     </li>",
"     <li>",
"      Children between 6 months and 2 years of age: 0.18 to 0.26",
"     </li>",
"     <li>",
"      Children between 2 and 5 years of age: 0.14",
"     </li>",
"     <li>",
"      Children between 6 and 12 years of age: 0.08",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary oxalate measurements may be falsely low in patients with renal insufficiency and progressive disease. In this setting, increased plasma oxalate and glycolate concentrations can be used to help support the diagnosis in patients with a glomerular filtration rate below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/40\">",
"     40",
"    </a>",
"    ]. In one study of children requiring hemodialysis, the mean plasma oxalate levels were much higher in patients with PH type 1 compared to those with other causes of ESRD (126 versus 44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated urinary oxalate excretion can be seen in patients with excess intake of oxalate (dietary hyperoxaluria), or in patients with increased intestinal oxalate absorption due to small bowel diseases (enteric hyperoxaluria). However, these levels are usually not as high as those seen in patients with PH type 1, and are typically below 1.0",
"    <span class=\"nowrap\">",
"     mmol/day",
"    </span>",
"    (90",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    although some patients with dietary hyperoxaluria may have urinary oxalate excretions rated between 1 and 2",
"    <span class=\"nowrap\">",
"     mmol/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H101664183\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since both type 1 and type 2 PH have elevated urinary oxalate excretion, they can be distinguished from one another by assessing the urinary excretion of glycolate and L-glyceric acid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"     22",
"    </a>",
"    ]. In general, hyperoxaluria plus increased urinary excretion of glycolate is strongly suggestive, but not absolutely diagnostic, of PH type 1 (normal urinary glycolate excretion of 0.5",
"    <span class=\"nowrap\">",
"     mmol/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day [45",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per day]). In contrast, patients with type 2 PH typically have elevated levels of L-glyceric acid (normal urinary excretion rate of",
"    <span class=\"nowrap\">",
"     &lt;5mmol/L).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H22971096\">",
"     'Primary hyperoxaluria type 2'",
"    </a>",
"    below.) .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82374407\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis is possible by molecular testing for mutations in the AGXT gene. Genetic testing options include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Targeted mutation analysis screens for the most common mutations of the AGXT gene. The detection rate is dependent on the number of mutations used in the screening panel but generally ranges from 50 to 70 percent. In one study, the most common mutation (p.Gly170Arg) was found in 37 percent of alleles followed by a frame shift mutation (c.33_34insC) in 11 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whole-gene sequencing will detect AGT mutations in almost all patients with PH type 1 (98 percent) and should be performed if there is a high clinical index of suspicion and a mutation is not identified by targeted mutation analysis.",
"     </li>",
"     <li>",
"      For prenatal diagnosis, linkage analysis may be used with polymorphic markers located in the AGXT gene when the family is informative but the specific mutation is not identified [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted previously, genotype analysis may give information on the possible responsiveness to pyridoxine as urinary oxalate excretion is significantly reduced in most patients with either the p.Gly170Arg or p.Phe152Ile mutations when they are treated with pyridoxine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41563359\">",
"     'Genotype/phenotype correlation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of PH type 1 needs to be confirmed prior to liver transplantation because it remains uncertain that liver transplantation is of benefit to patients with type 2 disease. (See",
"    <a class=\"local\" href=\"#H58182972\">",
"     'Transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A list of available laboratories for genetic testing can be found on the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests\">",
"     GeneReviews GeneTests laboratory directory",
"    </a>",
"    website.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101664099\">",
"    <span class=\"h4\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis can be made following mutation analysis of the index case and both parents. DNA obtained from chorionic villi or amniotic cells is analyzed for the identified mutations found in the family, allowing the detection of affected fetuses. Linkage analysis may also be used with polymorphic markers located in the AGXT gene when the family is informative but the specific mutation is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101664106\">",
"    <span class=\"h3\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, prior to the availability of genetic testing, the diagnosis of PH type 1 was confirmed by liver biopsy that demonstrated AGT deficiency. Evaluation of the hepatic tissue included quantification of enzymatic activity, an immunoblot to analyze the protein, and an immunoelectronic examination to demonstrate the virtual absence of AGT in the peroxisomes. AGT activity is less than 2 percent of normal in one-third of cases and ranges from 2 to 48 percent of normal in the remaining patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver biopsy to confirm the diagnosis is required prior to liver transplantation, if genetic testing is not available or a gene mutation has not been identified in a patient, in whom there is a strong clinical suspicion for PH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101664585\">",
"    <span class=\"h3\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of PH type 1 has been confirmed, further evaluation assesses the function of potentially affected organs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/34,39\">",
"     34,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal function is evaluated by obtaining serum creatinine levels as a measure of glomerular filtration rate (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone radiographs to detect radiodense metaphyseal bands and diffuse demineralization",
"     </li>",
"     <li>",
"      Thyroid function tests (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"       \"Laboratory assessment of thyroid function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrocardiogram to detect abnormalities in cardiac conduction",
"     </li>",
"     <li>",
"      Hemoglobin measurement to detect anemia due to chronic kidney disease or as a result of oxalate deposition in bone marrow",
"     </li>",
"     <li>",
"      In patients with systemic oxalosis, further evaluation to determine the extent of end-organ involvement should include eye evaluation (including slit lamp examination), bone density determination, electrocardiography, and echocardiography. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101664183\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PH type 1 includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other inborn errors of glyoxylate metabolism particularly type 2 or type 3 PH. (See",
"      <a class=\"local\" href=\"#H82374149\">",
"       'Metabolic testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H82374407\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ongoing increased oxalate intake due to consumption with foods rich in oxalate such as chocolate, cocoa, leafy green vegetables (eg, rhubarb and spinach), black teas, nuts, peanut butter, and starfish fruit [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased intestinal oxalate absorption associated with fat malabsorption due to small bowel disease or cystic fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H14#H14\">",
"       \"Chronic complications of the short bowel syndrome in children\", section on 'Hyperoxaluria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology of and risk factors for nephrolithiasis in children\", section on 'Hyperoxaluria and oxalosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Absence of intestinal oxalate degrading bacteria (Oxalobacter formigenes), and relative high oxalate diets or intestinal bowel disease and cystic fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metabolic screening and molecular testing differentiate these disorders from PH type 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of treatment in PH is dependent on early diagnosis. In particular, the initiation of medical management as soon as possible prolongs renal function, which delays end-stage renal disease (ESRD) and potentially minimizes non-renal sequelae. The definitive cure for PH type 1 is liver transplantation as the donor liver provides the missing enzyme, which lowers oxalate production to the normal range, but liver transplantation itself has significant complications and potential mortality. Also, the timing of such pre-emptive transplantation is difficult due to the heterogeneity of the disease. As a result, preemptive liver transplantation for PH type 1 remains controversial. (See",
"    <a class=\"local\" href=\"#H58182972\">",
"     'Transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58187731\">",
"    <span class=\"h3\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical management is focused on reduction of urinary calcium oxalate saturation and oxalate production, thereby minimizing renal oxalate deposition and delaying the progression of renal injury. (See",
"    <a class=\"local\" href=\"#H41563366\">",
"     'Oxalate deposition and renal injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Medical management includes the following modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1,37,39,43,44\">",
"     1,37,39,43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large fluid intake resulting in a high urinary output (greater than 3",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      per 1.73 m2) is the most effective therapy to decrease tubular fluid oxalate concentration and diminish intratubular oxalate deposition. A gastric tube or a percutaneous gastrostomy may be necessary in young children to maintain this high urine flow and urinary oxalate level during the night.",
"     </li>",
"     <li>",
"      Avoidance of foods with high oxalate content, such as tea, chocolate, spinach, and rhubarb. Intestinal oxalate absorption is lower in patients with PH compared to healthy subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/45\">",
"       45",
"      </a>",
"      ]; hence, a strict oxalate reduced diet is not necessary.",
"     </li>",
"     <li>",
"      A trial of high-dose pyridoxine (pyridoxal phosphate), a coenzyme of AGT that promotes the conversion of glyoxylate to glycine, rather than to oxalate. About 30 percent of patients with PH type 1 will response to pyridoxine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22,43\">",
"       22,43",
"      </a>",
"      ]. As a result, a trial of pyridoxine that lasts at least three to six months is warranted in all patients with type 1 PH [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"       22",
"      </a>",
"      ]. A positive response is defined as a reduction greater than 30 percent in urinary oxalate excretion. In patients who are responsive to pyridoxine, observational data show that benefit can be achieved in most patients at doses less than 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22,46\">",
"       22,46",
"      </a>",
"      ]. Pyridoxine therapy is continued indefinitely or until liver transplantation is performed. Large doses of pyridoxine may induce sensory neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We begin pyridoxine therapy at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and increase the dose (maximum dose, 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) if the patient remains unresponsive [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"       22",
"      </a>",
"      ]. The medication is discontinued if there is no significant decrease in urinary oxalate excretion.",
"     </li>",
"     <li>",
"      Urinary pyrophosphate, citrate, and magnesium, are inhibitors of calcium oxalate precipitation. Thus, the solubility of calcium oxalate may be increased by the administration of neutral phosphate (orthophosphate, in a dose of 30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      but higher during period of skeletal growth, maximum dose 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), potassium citrate (0.15",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/48\">",
"       48",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"       magnesium oxide",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      per m2). Orthophosphate should be discontinued in patients with impaired renal function to prevent phosphate accumulation and exacerbation of secondary hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"       \"Pathogenesis of renal osteodystrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/62/19432?source=see_link&amp;anchor=H13#H13\">",
"       \"Prevention of recurrent nephrolithiasis in children\", section on 'Hyperoxaluria and oxalosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enhancing oxalate elimination by the gastrointestinal tract is another potential method in reducing tissue and body oxalate levels. One proposed mechanism is the administration of Oxalobacter formigenes, an obligate anaerobic colonic bacterium which degrades endogenous oxalate, thereby reducing oxalate absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. However, in a clinical trial of 43 patients, there was no difference in the change in urinary oxalate between patients who received oral Oxalobacter formigenes therapy and those given placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/51\">",
"       51",
"      </a>",
"      ]. No serious adverse effects were reported. Further long-term studies are needed to determine whether Oxalobacter formigenes can effectively and safely prevent or slow the progression of ESRD in patients with primary hyperoxaluria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies illustrated the efficacy of medical management when started at an early age in patients with relatively normal renal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study, 25 patients with PH types I and II were treated with pyridoxine and orthophosphate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/43\">",
"       43",
"      </a>",
"      ]. Oxalate excretion fell by about 10 percent; this effect plus the increase in excretion of inhibitors of crystallization led to a substantial reduction in urinary calcium oxalate supersaturation. The mean fall in glomerular filtration rate was only 1.5",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year and estimated renal survival was 89 percent at 10 years and 74 percent at 20 years. Although there was no control group, previous reports suggested a 20-year renal survival of only 20 percent in untreated patients.",
"     </li>",
"     <li>",
"      In a multicenter retrospective study, 20 of 22 children with type I PH (median age at diagnosis, 2.4 years) who were treated with medical management did not require renal replacement at a median follow-up of 8.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/52\">",
"       52",
"      </a>",
"      ]. Treatment was initiated at a median age of 4.2 years and included aggressive daily fluid intake, urine alkalinization with sodium or potassium citrate, or sodium or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      , magnesium supplementation, and in some cases pyridoxine. The majority of patients had a stable estimated GFR. Seven patients had a decline of over 20",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      in their estimated GFR during the study period. Multivariate analysis demonstrated deterioration of renal function was associated with a delay in the initiation of therapy suggesting that irreversible progressive renal damage may have occurred before medical therapy was started.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22970959\">",
"    <span class=\"h3\">",
"     Urological treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervention is required when stones obstruct the urinary tract. Nephrostomy, ureteroscopy, and ureteral JJ stent are preferred interventions for stone removal. Open surgical removal may precipitate acute renal failure and extracorporeal shock-wave lithotripsy may harm the kidney because of the potential presence of nephrocalcinosis and microlithiasis within the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute management of nephrolithiasis in children\", section on 'Urologic intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22970966\">",
"    <span class=\"h3\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximal oxalate elimination via conventional hemodialysis (HD) and peritoneal dialysis (PD) is 950 to 1440",
"    <span class=\"nowrap\">",
"     micromol/day,",
"    </span>",
"    which is significantly lower than the daily oxalate production of 3500 to 7500 micromol in patients with PH type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/54\">",
"     54",
"    </a>",
"    ]. As a consequence, despite standard maintenance dialysis therapy, plasma oxalate increases and typically exceeds the supersaturation threshold of 30",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    increasing the risk and progression of systemic oxalosis. (See",
"    <a class=\"local\" href=\"#H41563366\">",
"     'Oxalate deposition and renal injury'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H82373131\">",
"     'Systemic oxalosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intensive dialysis (eg, five-hour daily HD sessions or a combination of HD and PD) is needed to try to match daily oxalate production, but in many patients, even intensive dialysis therapy remains inadequate to keep up with their daily oxalate production [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/55\">",
"     55",
"    </a>",
"    ]. Intensive dialysis therapy may be useful prior to renal transplantation to decrease plasma oxalate as much as possible to reduce subsequent oxalate deposition and injury in the renal allograft. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Isolated renal transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58182972\">",
"    <span class=\"h3\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal transplantation strategy for patients with PH type 1 remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/56\">",
"     56",
"    </a>",
"    ]. Three different transplant options are available.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Combined liver-kidney transplantation",
"     </li>",
"     <li>",
"      Isolated liver transplantation",
"     </li>",
"     <li>",
"      Isolated renal transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Liver transplantation is the only curative intervention for PH type 1 as it corrects the underlying enzymatic defect due to mutations of the AGXT gene. Preemptive liver transplant in patients with glomerular filtration rates greater than 40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per 1.73 m2 has been proposed as curative treatment in patients with type 1 disease. However, this presupposes progression of kidney disease despite aggressive medical management, and exposes the patient to the known risk factors associated with liver transplantation and removal of the native liver, which is totally normal except for the absence or reduction in AGT activity. Complications include those due to immunosuppressive therapy (eg, infections or adverse drug effects), secondary malignancy, and failure of the liver allograft. If preemptive liver transplantation is considered, the optimal timing is unknown, as there are no data that provide an accurate prediction of the clinical course in patients who are diagnosed in a timely manner (prior to significant renal damage) and treated with aggressive medical management, especially patients who are responsive to pyridoxine therapy.",
"   </p>",
"   <p>",
"    In patients with significant chronic kidney disease, mobilization of oxalate within the tissues is reduced because of the impaired renal function after liver transplantation alone. In these patients, combined liver-kidney transplantation has been advocated over isolated renal transplantation as it provides renal replacement intervention and a cure to the underlying metabolic problem. However, the limited long-term outcome comparing these different approaches is insufficient to determine the optimal approach. As an example, death-censored renal allograft survival is greater in patients with significant CKD who receive a combined liver-kidney transplantation but patient survival may be similar or even lower [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The duration of renal allograft survival is also unknown in patients with isolated renal transplantation who are treated with intensive medical therapy immediately after transplantation, especially those who are responsive to pyridoxine therapy.",
"   </p>",
"   <p>",
"    Regardless of when the choice of transplantation is made, the procedure should be performed at a center with expertise in transplantation and the care of patients with PH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Combined liver-kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined liver-kidney transplantation has increasingly become the treatment used in children with PH type 1 with progressive renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1,25,33,43,48,53,56,58,59\">",
"     1,25,33,43,48,53,56,58,59",
"    </a>",
"    ]. The liver provides the missing enzyme, thereby lowering oxalate production to the normal range. This modality should be considered only after confirming that the diagnosis is PH type 1. The outcome of simultaneous transplantation is probably best when the procedure is performed as the glomerular filtration rate (GFR) falls to 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and prior to marked tissue oxalate deposition.",
"   </p>",
"   <p>",
"    In a case series of patients with PH who underwent primary renal transplantation, those who received a concurrent liver transplant (n = 26) compared to those with an isolated renal transplantation (n=32) had similar five-year graft survival (48 versus 45 percent) but a lower patient survival rate (67 versus 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients with combined liver-kidney transplantation had a higher five-year death-censored graft survival (71 versus 45 percent), but all three patients who died with a functioning kidney received combined liver-kidney transplantation. Of note, patients with only renal transplants had a greater delay in diagnosis (including 11 patients who were undiagnosed at the time of transplantation) and were more likely to have their transplantation performed before 2000.",
"   </p>",
"   <p>",
"    Another option is sequential transplantation (first liver followed by kidney transplantation), which has been performed in small children with PH type 1 and ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The rationale underlying this approach is the initial liver transplant will result in a decrease in plasma oxalate, thereby reducing the risk of kidney injury after renal transplantation. In addition, sequential transplantation may be performed in small recipients in whom a combined simultaneous transplantation is not feasible because of anatomical reasons or medical instability [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/59,62\">",
"     59,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After transplantation, there is gradual mobilization of tissue oxalate deposits, and elevated urinary oxalate excretion may persist for as long or even longer than two years as tissue stores are removed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/56\">",
"     56",
"    </a>",
"    ]. The same management strategies used for patients with isolated renal transplant are employed in patients undergoing combined liver-kidney transplantation to decrease hyperoxaluria and hyperoxalemia exposure to the transplanted kidney. This includes aggressive medical management (high fluid intake, and the administration of neutral phosphate, potassium citrate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"     magnesium oxide",
"    </a>",
"    ), and the administration of pyridoxine in responsive patients. The duration of medical intervention is decided on an individual basis as the amount of tissue stores vary. (See",
"    <a class=\"local\" href=\"#H58187731\">",
"     'Medical management'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Isolated renal transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58184340\">",
"    <span class=\"h4\">",
"     Isolated liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated liver transplantation has been proposed for patients with rapidly progressive disease who still have a glomerular filtration rate between 40 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/61\">",
"     61",
"    </a>",
"    ]. Case reports reported preemptive isolated liver transplantation resulted in long-term enhanced renal function in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/61,63,64\">",
"     61,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, liver transplantation requires native hepatectomy, even though the liver is normal in all other aspects, because any remaining defective hepatic cells will continue to produce large amounts of oxalate. However, the significant morbidity and mortality associated with liver transplantation has led to hesitation to adopt preemptive liver transplantation in the absence of significant renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/57\">",
"     57",
"    </a>",
"    ]. In particular, the improved renal survival associated with early diagnosis and initiation of intense medical therapy also has contributed to the reluctance to adopt this approach. In one case series of 13 patients, two patients who were to undergo sequential liver and renal transplantation, died early after initial liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Isolated renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated renal transplantation has generally been supplanted by combined liver and renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/56\">",
"     56",
"    </a>",
"    ], because the experience of renal transplantation alone in PH had been relatively disappointing, as oxalate deposition from newly formed and mobilized tissue oxalate led to loss of the allograft in many patients.",
"   </p>",
"   <p>",
"    Data from the European Dialysis and Transplant Association in 98 first transplants prior to 1990, for example, showed a three year graft survival rate of only 23 percent for living related donor kidneys and 17 percent for cadaver kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/65\">",
"     65",
"    </a>",
"    ]. Similarly dismal results were observed in a report of a single center's transplantation experience [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a number of manipulations have improved subsequent outcome of renal transplantation. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1,67\">",
"     1,67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive preoperative dialysis (as often as six days per week) to reduce urinary and systemic oxalate levels",
"     </li>",
"     <li>",
"      Consideration of early transplantation as the glomerular filtration rate falls below 20",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      to minimize systemic oxalate accumulation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delayed use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      because of its potential nephrotoxic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posttransplant management that includes aggressive medical management (high fluid intake, and the administration of neutral phosphate, potassium citrate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"       magnesium oxide",
"      </a>",
"      ). In addition, in some cases especially when renal function is impaired, dialysis may be performed to decrease the exposure of hyperoxaluria and hyperoxalemia to the transplanted kidney. (See",
"      <a class=\"local\" href=\"#H58187731\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of pyridoxine in responsive patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated kidney transplantation may be an option in patients who respond to pyridoxine and have minimal oxalate deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/39,69\">",
"     39,69",
"    </a>",
"    ], and possibly adults with a late-onset form of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332267\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our current practice is combined liver-kidney transplantation for children with PH type 1. Because medical therapy has significantly slowed the progression to ESRD, we generally will not consider isolated liver transplantation, except for patients, in whom there is a rapid deterioration of renal function, despite intensive medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22971096\">",
"    <span class=\"h1\">",
"     PRIMARY HYPEROXALURIA TYPE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;PH type 2 (MIM #260000) is generally a milder disease than PH type 1 and accounts for 10 percent of all cases of PH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/7\">",
"     7",
"    </a>",
"    ]. Since the 1990s, there has been increased recognition and identification of this entity because of the greater availability of molecular testing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60191620\">",
"    <span class=\"h2\">",
"     Pathogenesis and genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In PH type 2, the genetic defect leads to decreased or absent activity of glyoxylate",
"    <span class=\"nowrap\">",
"     reductase/hydroxypyruvate",
"    </span>",
"    reductase (GRHPR), which normally is involved in the conversion of glyoxylate to glycolate. Unlike the AGT of PH type 1, this enzyme is not restricted only to the liver. This inborn error of metabolism results in increased amounts of glyoxylate and hydroxypyruvate, which are converted by lactate dehydrogenase to oxalate and L-glyceric acid. These metabolites are excreted in excessive amounts in the urine, and in the case of oxalate, leads to recurrent urolithiasis.",
"   </p>",
"   <p>",
"    The GRHPR gene maps to chromosome 9p11 and encodes for a 36 kDa protein [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"     22",
"    </a>",
"    ]. As of 2011, 20 mutations have been described and include deletions, insertions, missense, and nonsense mutations. The most common mutation occurring in about 40 percent of cases is a deletion of a single base pair in exon 2 (c.103delG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60191838\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of PH type 2, the ability to compare the clinical features of both PH types 1 and 2 has been extremely difficult. Patients with PH type 2 compared to those with type 1 disease appear to have less severe disease with better preservation of renal function over time. The difference may be explained by the lower oxalate excretion that is generally seen in patients with type 2 disease, although there is significant overlap between the two forms of PH.",
"   </p>",
"   <p>",
"    In a report of 12 and 8 patients with types 1 and 2 disease, respectively, the age of onset of symptoms, and the initial serum creatinine and oxalate concentrations were similar with both forms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/70\">",
"     70",
"    </a>",
"    ]. However, progression to end-stage renal disease (ESRD) was only observed among those with type 1 disease (four patients at 10 years compared with none of those with type II disease at 18 years), which may have been due in part to significantly higher urinary oxalate excretion rates. In another study of 13 patients with type 2 disease, only one patient had a significant decline in renal function after a median follow-up of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/71\">",
"     71",
"    </a>",
"    ]. This patient also had nephrocalcinosis, which is less commonly seen in patients with type 2 disease.",
"   </p>",
"   <p>",
"    The primary clinical manifestations of PH type 2 are those associated with recurrent episodes of urolithiasis. These include gross hematuria, renal colic, urinary tract infection, and, infrequently urinary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/71\">",
"     71",
"    </a>",
"    ]. Nephrocalcinosis is less common in patients with PH type 2 than those with type 1 disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60191921\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PH type 2 is based on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of urolithiasis and, rarely, nephrocalcinosis in an infant or child.",
"     </li>",
"     <li>",
"      Metabolic screening that demonstrates elevated urinary oxalate that is described previously. In addition, patients with PH type 2 typically have urinary L&mdash;glycerate, which is pathognomonic for type 2 disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/72\">",
"       72",
"      </a>",
"      ], whereas patients with type 1 disease typically have elevated urinary glycolate excretion. (See",
"      <a class=\"local\" href=\"#H82374149\">",
"       'Metabolic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definite diagnosis of PH type 2 is made by either:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A liver biopsy that demonstrates decreased GRHPR activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Molecular testing, which is increasingly performed to confirm the diagnosis of PH type 2. A two-step approach is usually used. The initial step involves sequence analysis of exons 2 and 4 to detect the two most common mutation, c.103delG (40 percent) in exon 2 and c.403_405+2 del AAGT (16 percent) in exon 4 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/73\">",
"       73",
"      </a>",
"      ]. If no mutation is detected, the second step of complete sequencing is performed. Because closely linked markers have been identified for GRHPR, linkage analysis can be used to screen for other family members once an index case has been identified if the causative mutation is not known. Laboratories that perform genetic testing for PH type 2 are listed on the",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests\">",
"       GeneReviews GeneTests laboratory directory",
"      </a>",
"      website.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60192128\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PH type 2 is similar to that of PH type 1 and includes other inborn errors of glyoxylate metabolism, increased oxalate consumption, and small bowel disorders that enhance oxalate reabsorption. (See",
"    <a class=\"local\" href=\"#H101664183\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60192112\">",
"    <span class=\"h2\">",
"     Evaluation after diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to PH type 1, once the diagnosis of PH type 2 is established, assessment of the function of potentially affected organs should be performed. This includes evaluation of renal, cardiac, and thyroid function, and examination of the retina and bone radiographs and density to detect and assess the amount of oxalate deposition. (See",
"    <a class=\"local\" href=\"#H101664585\">",
"     'Further evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60192167\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of PH type 2 is focused on reducing urinary oxalate by intensive medical management that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High fluid intake (greater than 3",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      per 1.73 m2) to decrease tubular fluid oxalate concentration and diminish crystallization and stone formation.",
"     </li>",
"     <li>",
"      Urinary pyrophosphate, citrate, and magnesium, are inhibitors of calcium oxalate precipitation. Thus, the solubility of calcium oxalate may be increased by the administration of neutral phosphate (orthophosphate, in a dose of 30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      potassium citrate (0.15",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/48\">",
"       48",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"       magnesium oxide",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      per m2). Orthophosphate should be discontinued if the patient progresses to renal failure to prevent phosphate accumulation and exacerbation of secondary hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"       \"Pathogenesis of renal osteodystrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/62/19432?source=see_link&amp;anchor=H13#H13\">",
"       \"Prevention of recurrent nephrolithiasis in children\", section on 'Hyperoxaluria and oxalosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike type 1 disease, pyridoxine therapy does not reduce oxalate production, and is not useful in patients with PH type 2.",
"   </p>",
"   <p>",
"    In the few patients who progress to end-stage renal disease (ESRD), isolated kidney transplantation is the recommended approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/22,56\">",
"     22,56",
"    </a>",
"    ]. Liver transplantation is not indicated in patients with type 2 disease, because GRHPR is found in multiple body tissues (unlike AGT in PH type 1, which is only found in hepatocytes). As a result, there is no evidence that liver transplantation corrects the inborn error of glyoxylate metabolism in patients with type 2 disease. A definitive diagnosis that differentiates PH type 2 from type 1 is needed to decide on the best approach for transplantation in patients with ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94201825\">",
"    <span class=\"h1\">",
"     PRIMARY HYPEROXALURIA TYPE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;PH type 3 (MIM #613) accounts for about 5 percent of patients. It is due to mutations in the HOGA1 gene (formerly DHDPSL",
"    <em>",
"    </em>",
"    gene) that encodes the mitochondrial 4-hydroxy-2-oxoglutarate aldolase enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/10,74\">",
"     10,74",
"    </a>",
"    ]. This enzyme is the final step of the hydroxyproline degradation pathway within the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/75\">",
"     75",
"    </a>",
"    ]. Idiopathic calcium oxalate stones have been observed in individuals with heterozygous mutations of the HOGA1",
"    <em>",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PH type 3 typically present early in life (mean age two years) with symptoms due to recurrent urolithiasis (eg, hematuria, pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urinary tract infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/10\">",
"     10",
"    </a>",
"    ]. Hyperoxaluria is often associated with hypercalcuria. Unlike the other two forms of PH, PH type 3 becomes clinically silent later in life without recurrence of nephrolithiasis after six years of age, and does not progress to renal failure. In one case series of PH type 3, half of the families were of Ashkenazi Jewish descent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109556471\">",
"    <span class=\"h1\">",
"     OTHER FORMS OF PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 5 percent of patients with PH do not have identifiable genetic mutations of the AGXT, GRHPR, or HOGA1 gene.",
"   </p>",
"   <p>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information about primary hyperoxaluria for patients can be obtained from the Oxalosis and Hyperoxaluria Foundation:",
"   </p>",
"   <p>",
"    &nbsp;The Oxalosis and Hyperoxaluria Foundation",
"   </p>",
"   <p>",
"    201 East 19",
"    <sup>",
"     th",
"    </sup>",
"    Street, Suite 12E",
"   </p>",
"   <p>",
"    New York, NY 10003",
"   </p>",
"   <p>",
"    212-777-0470",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.ohf.org/\">",
"     www.ohf.org",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;e-mail:",
"    <a class=\"external\" href=\"mailto:OHF@OHFUltranet.com\">",
"     OHF@OHFUltranet.com",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;OxalEurope",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.oxaleurope.org/\">",
"     www.OxalEurope.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60192426\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperoxaluria (PH) is a rare inborn error of glyoxylate metabolism characterized by the overproduction of oxalate, which is deposited as calcium oxalate in various organs. In particular, the kidney is a prime target for oxalate deposition, which in some cases, may lead to end-stage renal disease (ESRD).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PH is primarily caused by autosomal recessive enzymatic defects in pathways of glyoxylate metabolism that result in enhanced oxalate production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      PH type 1 (about 80 percent of cases) is due to mutations of hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary hyperoxaluria type 1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PH type 2 (10 percent of cases) is due to mutations of glyoxylate",
"      <span class=\"nowrap\">",
"       reductase/hydroxypyruvate",
"      </span>",
"      reductase (GRHPR). (See",
"      <a class=\"local\" href=\"#H22971096\">",
"       'Primary hyperoxaluria type 2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PH type 3 (5 percent of cases) is due to mutations of the HOGA1 gene (formerly DHDPSL",
"      <em>",
"      </em>",
"      gene) that encodes the mitochondrial 4-hydroxy-2-oxoglutarate aldolase enzyme, which catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate. (See",
"      <a class=\"local\" href=\"#H94201825\">",
"       'Primary hyperoxaluria type 3'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with PH, the increased urinary excretion of oxalate results in an oversaturated urine for calcium oxalate, which leads to urolithiasis and nephrocalcinosis. Recurrent stones and progressive nephrocalcinosis cause renal parenchymal inflammation and fibrosis, and if persistent, may progress to ESRD. As renal function deteriorates, plasma oxalate exceeds 30",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"      (the plasma supersaturation threshold for calcium oxalate), because of reduced urinary oxalate excretion. This leads to calcium oxalate deposition into nonrenal tissues including the retina, myocardium, vessel walls, skin, bone, and the central nervous system (systemic oxalosis). (See",
"      <a class=\"local\" href=\"#H41563366\">",
"       'Oxalate deposition and renal injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of PH type 1 varies dependent on age and clinical findings because of marked heterogeneity of disease expression. Affected infants and children generally present with symptoms related to nephrocalcinosis, urolithiasis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic kidney disease (CKD). ESRD develops in approximately one-half of patients by young adulthood. As renal function deteriorates, nonrenal manifestations due to systemic oxalosis develop and include cardiac conduction defects, bony pain and increased risk of fractures, and diminished visual acuity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical and laboratory manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PH type 2 generally have less severe disease than those with PH type 1. Patients primarily present with recurrent urolithiasis and are less likely to have nephrocalcinosis and rarely progress to ESRD. (See",
"      <a class=\"local\" href=\"#H60191838\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PH type 3 generally present early in life (mean age, two years) with nephrolithiasis. In contrast to the other two forms of PH, patients with PH type 3 typically do not have recurrent nephrolithiasis after six years and do not progress to ESRD. (See",
"      <a class=\"local\" href=\"#H94201825\">",
"       'Primary hyperoxaluria type 3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnoses of PH are based on recognition of clinical findings suggestive of PH (eg, recurrent urolithiasis or nephrocalcinosis), a markedly increased urinary oxalate excretion, and confirmation by molecular genetic testing. In some cases, liver biopsy demonstrating decreased or absent activity of AGT for type 1 disease and GRHPR for type 2 is used to confirm the diagnosis.",
"     </li>",
"     <li>",
"      Prior to genetic testing, metabolic testing is useful in differentiation among the types 1 and 2 PH as urinary excretion of glycolate is strongly suggestive, but not absolutely diagnostic, of PH type 1, and patients with type 2 PH typically have elevated levels of L-glyceric acid. (See",
"      <a class=\"local\" href=\"#H82374142\">",
"       'Clinical diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H60191921\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential of PH includes secondary oxalosis due to increased oxalate intake or oxalate reabsorption due to small bowel disease. The different forms of PH are distinguished from each other and other inborn error of oxalate and secondary causes of oxaluria by the metabolic screening and molecular testing. (See",
"      <a class=\"local\" href=\"#H101664183\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PH should be diagnosed as soon as possible to initiate the following medical interventions to reduce calcium oxalate deposition and renal impairment in patients with type 1 and 2 PH. (See",
"      <a class=\"local\" href=\"#H58187731\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend high fluid intake (greater than 3",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      per 1.73 m2) to decrease tubular fluid oxalate concentration and diminish intratubular oxalate deposition with a goal of urinary oxalate concentration below 0.4",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      throughout the entire 24-hour day (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend the use neutral phosphate (orthophosphate, in a dose of 30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      but higher during period of skeletal growth), potassium citrate (0.15",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/55/12154/abstract/48\">",
"       48",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"       magnesium oxide",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      per m2) to reduce urinary calcium oxalate precipitation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with PH type 1, we recommend a three to six month trial of pyridoxine (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In about 30 percent of patients with PH type 1, pyridoxine reduces urinary oxalate secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with PH type 1 disease, although three transplant options are currently available, it remains unclear what is the optimal approach. Until more data are available that better inform us regarding treatment choice, we perform a combination of liver-renal transplantation in patients with renal function impairment. (See",
"      <a class=\"local\" href=\"#H58182972\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PH type 2 disease and ESRD, we suggest renal transplantation alone as the preferred procedure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H60192167\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/1\">",
"      Watts RW. Primary hyperoxaluria type I. QJM 1994; 87:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/2\">",
"      Danpure CJ. Molecular and clinical heterogeneity in primary hyperoxaluria type 1. Am J Kidney Dis 1991; 17:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/3\">",
"      Cochat P. Primary hyperoxaluria type 1. Kidney Int 1999; 55:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/4\">",
"      Devonald MA, Karet FE. Renal epithelial traffic jams and one-way streets. J Am Soc Nephrol 2004; 15:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/5\">",
"      Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2012; 8:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/6\">",
"      Danpure CJ. Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Nephrol Dial Transplant 1995; 10 Suppl 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/7\">",
"      Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 2003; 18:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/8\">",
"      Seargeant LE, deGroot GW, Dilling LA, et al. Primary oxaluria type 2 (L-glyceric aciduria): a rare cause of nephrolithiasis in children. J Pediatr 1991; 118:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/9\">",
"      Monico CG, Persson M, Ford GC, et al. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int 2002; 62:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/10\">",
"      Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010; 87:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/11\">",
"      Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/12\">",
"      Cochat P, Deloraine A, Rotily M, et al. Epidemiology of primary hyperoxaluria type 1. Soci&eacute;t&eacute; de N&eacute;phrologie and the Soci&eacute;t&eacute; de N&eacute;phrologie P&eacute;diatrique. Nephrol Dial Transplant 1995; 10 Suppl 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/13\">",
"      Kopp N, Leumann E. Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant 1995; 10:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/14\">",
"      Takada Y, Kaneko N, Esumi H, et al. Human peroxisomal L-alanine: glyoxylate aminotransferase. Evolutionary loss of a mitochondrial targeting signal by point mutation of the initiation codon. Biochem J 1990; 268:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/15\">",
"      Purdue PE, Lumb MJ, Fox M, et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991; 10:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/16\">",
"      Danpure CJ, Jennings PR, Fryer P, et al. Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity. J Inherit Metab Dis 1994; 17:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/17\">",
"      Williams EL, Acquaviva C, Amoroso A, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 2009; 30:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/18\">",
"      Monico CG, Rossetti S, Schwanz HA, et al. Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. J Am Soc Nephrol 2007; 18:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/19\">",
"      Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005; 67:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/20\">",
"      Harambat J, Fargue S, Acquaviva C, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 2010; 77:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/21\">",
"      Cellini B, Montioli R, Paiardini A, et al. Molecular Insight into the Synergism between the Minor Allele of Human Liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I Mutation. J Biol Chem 2009; 284:8349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/22\">",
"      Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009; 75:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/23\">",
"      Hoppe B. Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1. Kidney Int 2010; 77:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/24\">",
"      Cochat P, Liutkus A, Fargue S, et al. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006; 21:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/25\">",
"      Millan MT, Berquist WE, So SK, et al. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 2003; 76:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/26\">",
"      Cochat P, Koch Nogueira PC, Mahmoud MA, et al. Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr 1999; 135:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/27\">",
"      van Woerden CS, Groothoff JW, Wanders RJ, et al. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 2003; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/28\">",
"      Latta K, Brodehl J. Primary hyperoxaluria type I. Eur J Pediatr 1990; 149:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/29\">",
"      Amoroso A, Pirulli D, Florian F, et al. AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol 2001; 12:2072.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2008 https://web.emmes.com/study/ped/announce.htm (Accessed on October 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/31\">",
"      Morgan SH, Purkiss P, Watts RW, Mansell MA. Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria. Nephron 1987; 46:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/32\">",
"      Mookadam F, Smith T, Jiamsripong P, et al. Cardiac abnormalities in primary hyperoxaluria. Circ J 2010; 74:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/33\">",
"      Small KW, Scheinman J, Klintworth GK. A clinicopathological study of ocular involvement in primary hyperoxaluria type I. Br J Ophthalmol 1992; 76:54.",
"     </a>",
"    </li>",
"    <li>",
"     Coulter-Mackie, MB, White, CT, Hurley, RM, et al. Primary Hyperoxaluria Type 1. GeneReviews. file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ph1 (Accessed on October 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/35\">",
"      Blackmon JA, Jeffy BG, Malone JC, Knable AL Jr. Oxalosis involving the skin: case report and literature review. Arch Dermatol 2011; 147:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/36\">",
"      Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 2005; 25:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/37\">",
"      Hoppe B, Latta K, von Schnakenburg C, Kemper MJ. Primary hyperoxaluria--the German experience. Am J Nephrol 2005; 25:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/38\">",
"      Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol 2005; 25:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/39\">",
"      Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012; 27:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/40\">",
"      Hoppe B, Kemper MJ, B&ouml;kenkamp A, Langman CB. Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int 1998; 54:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/41\">",
"      Hoppe B, Kemper MJ, B&ouml;kenkamp A, et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999; 56:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/42\">",
"      Rumsby G, Mandel H, Avey C, Geraerts A. Polymorphisms in the alanine:glyoxylate aminotransferase gene and their application to the prenatal diagnosis of primary hyperoxaluria type 1. Nephrol Dial Transplant 1995; 10 Suppl 8:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/43\">",
"      Milliner DS, Eickholt JT, Bergstralh EJ, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994; 331:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/44\">",
"      Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant 2005; 20:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/45\">",
"      Sikora P, von Unruh GE, Beck B, et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008; 73:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/46\">",
"      Rumsby G, Williams E, Coulter-Mackie M. Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Kidney Int 2004; 66:959.",
"     </a>",
"    </li>",
"    <li>",
"     Cochat, P, Collard, LB. Primary hyperoxaluria. In: Pediatric Nephrology, 5th ed, Avner, ED, Harmon, WE, Niaudet, P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/48\">",
"      Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 1993; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/49\">",
"      Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/50\">",
"      Hatch M, Gjymishka A, Salido EC, et al. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011; 300:G461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/51\">",
"      Hoppe B, Groothoff JW, Hulton SA, et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011; 26:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/52\">",
"      Fargue S, Harambat J, Gagnadoux MF, et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 2009; 76:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/53\">",
"      Grateau G, Gr&uuml;nfeld JP, Beurton D, et al. Post-surgical deterioration of renal function in primary hyperoxaluria. Nephrol Dial Transplant 1987; 1:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/54\">",
"      Hoppe B, Graf D, Offner G, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 1996; 10:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/55\">",
"      Illies F, Bonzel KE, Wingen AM, et al. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 2006; 70:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/56\">",
"      Bergstralh EJ, Monico CG, Lieske JC, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant 2010; 10:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/57\">",
"      Scheinman JI. Liver transplantation in oxalosis prior to advanced chronic kidney disease. Pediatr Nephrol 2010; 25:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/58\">",
"      Jeyarajah DR, McBride M, Klintmalm GB, Gonwa TA. Combined liver-kidney transplantation: what are the indications? Transplantation 1997; 64:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/59\">",
"      Brinkert F, Ganschow R, Helmke K, et al. Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation 2009; 87:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/60\">",
"      Malla I, Lysy PA, Godefroid N, et al. Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation. Pediatr Transplant 2009; 13:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/61\">",
"      Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 2010; 15:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/62\">",
"      Kemper MJ. Concurrent or sequential liver and kidney transplantation in children with primary hyperoxaluria type 1? Pediatr Transplant 2005; 9:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/63\">",
"      Gruessner RW. Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I. N Engl J Med 1998; 338:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/64\">",
"      Galanti M, Contreras A. Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1. Pediatr Nephrol 2010; 25:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/65\">",
"      Broyer M, Brunner FP, Brynger H, et al. Kidney transplantation in primary oxalosis: data from the EDTA Registry. Nephrol Dial Transplant 1990; 5:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/66\">",
"      M&uuml;ller T, Sikora P, Offner G, et al. Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center. Clin Nephrol 1998; 49:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/67\">",
"      Scheinman JI, Najarian JS, Mauer SM. Successful strategies for renal transplantation in primary oxalosis. Kidney Int 1984; 25:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/68\">",
"      Watts RW, Morgan SH, Purkiss P, et al. Timing of renal transplantation in the management of pyridoxine-resistant type I primary hyperoxaluria. Transplantation 1988; 45:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/69\">",
"      Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/70\">",
"      Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001; 59:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/71\">",
"      Johnson SA, Rumsby G, Cregeen D, Hulton SA. Primary hyperoxaluria type 2 in children. Pediatr Nephrol 2002; 17:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/72\">",
"      Chlebeck PT, Milliner DS, Smith LH. Long-term prognosis in primary hyperoxaluria type II (L-glyceric aciduria). Am J Kidney Dis 1994; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     Rumsby, G. Primary hyperoxaluria Type 2. Gene Reviews. file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ph2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/74\">",
"      Williams EL, Bockenhauer D, van't Hoff WG, et al. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 2012; 27:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/75\">",
"      Riedel TJ, Knight J, Murray MS, et al. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 2012; 1822:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/55/12154/abstract/76\">",
"      Monico CG, Rossetti S, Belostotsky R, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 2011; 6:2289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6141 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12154=[""].join("\n");
var outline_f11_55_12154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H60192426\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY HYPEROXALURIA TYPE 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543655503\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41563359\">",
"      - Genotype/phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41563366\">",
"      - Oxalate deposition and renal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical and laboratory manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16756187\">",
"      - Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82373131\">",
"      - Systemic oxalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82374142\">",
"      - Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H82374149\">",
"      Metabolic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82374407\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H101664099\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101664106\">",
"      - Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101664585\">",
"      - Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101664183\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58187731\">",
"      - Medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22970959\">",
"      - Urological treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22970966\">",
"      - Dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58182972\">",
"      - Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combined liver-kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H58184340\">",
"      Isolated liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Isolated renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H332267\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22971096\">",
"      PRIMARY HYPEROXALURIA TYPE 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60191620\">",
"      Pathogenesis and genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60191838\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60191921\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60192128\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60192112\">",
"      Evaluation after diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60192167\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94201825\">",
"      PRIMARY HYPEROXALURIA TYPE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109556471\">",
"      OTHER FORMS OF PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60192426\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6141|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/45/735\" title=\"diagnostic image 1\">",
"      Renal stones in primary oxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6141|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42302\" title=\"picture 1\">",
"      Calcium oxalate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10561\" title=\"picture 2\">",
"      Ca oxalate monohydrate crystals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=related_link\">",
"      Acute management of nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=related_link\">",
"      Epidemiology of and risk factors for nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/62/19432?source=related_link\">",
"      Prevention of recurrent nephrolithiasis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_55_12155="Characteristic serious headache";
var content_f11_55_12155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of headache with serious underlying pathology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       History",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Explosive onset and severe at onset",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No similar headaches in the past",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Concomitant infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Altered mental status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Headache with exertion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age over 50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunosuppression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurologic abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased level of consciousness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meningismus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toxic appearance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papilledema",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12155=[""].join("\n");
var outline_f11_55_12155=null;
var title_f11_55_12156="Heat stroke versus heat exhaustion";
var content_f11_55_12156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of heat stroke and heat exhaustion*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Heat stroke",
"      </td>",
"      <td class=\"subtitle1\">",
"       Heat exhaustion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Core body temperature",
"      </td>",
"      <td>",
"       &gt;40&deg;C (104&deg;F)&bull;",
"      </td>",
"      <td>",
"       &le;40&deg;C (104&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mental status",
"      </td>",
"      <td>",
"       Abnormal mental status (eg, obtunded, coma, delirium, hallucinations, seizures, ataxia, slurred speech)",
"      </td>",
"      <td>",
"       Normal mental status, dizziness, or mild confusion that rapidly normalizes within 30 minutes of treatment. May see syncope with rapid recovery of alertness.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Airway and breathing",
"      </td>",
"      <td>",
"       May be compromised due to altered mental status, tachypneic",
"      </td>",
"      <td>",
"       Clear airway, may be tachypneic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Circulation",
"      </td>",
"      <td>",
"       Tachycardia with hypotension, moderate to severe dehydration",
"      </td>",
"      <td>",
"       Tachycardia with normal blood pressure, mild to moderate dehydration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skin findings",
"      </td>",
"      <td>",
"       Dry skin (classic heat stroke) or sweating (exertional heat stroke)",
"      </td>",
"      <td>",
"       Sweating",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other clinical features",
"      </td>",
"      <td>",
"       <p>",
"        - Vomiting",
"       </p>",
"       <p>",
"        - Diarrhea",
"       </p>",
"       <p>",
"        - Clinical and laboratory findings of DIC, rhabdomyolysis, acute renal failure, cardiogenic shock, and liver failure",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        - Nausea, vomiting",
"       </p>",
"       <p>",
"        - Headache",
"       </p>",
"       <p>",
"        - Fatigue, weakness",
"       </p>",
"       <p>",
"        - In some patients, hyponatremia or hypernatremia",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For a discussion of treatment see appropriate topics.",
"     <br>",
"      &bull; Some patients with heat stroke may have a core body temperature &lt;40&deg;C (104&deg;F) if cooling measures were initiated in the prehospital setting.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Jardine, DS. Heat illness and heat stroke. Pediatr Rev 2007; 28:249.",
"      <br>",
"       2. Glazer, JL. Management of heatstroke and heat exhaustion. Am Fam Physician 2005; 71:2133.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12156=[""].join("\n");
var outline_f11_55_12156=null;
var title_f11_55_12157="Causes of FHF";
var content_f11_55_12157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67925%7EGAST%2F74040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67925%7EGAST%2F74040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mnemonic for causes of acute liver failure: The ABCs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        Acetaminophen, hepatitis A, autoimmune hepatitis,",
"        <em>",
"         Amanita phalloides",
"        </em>",
"        (mushroom poisoning), adenovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        Hepatitis B, Budd-Chiari syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        Cryptogenic, hepatitis C, CMV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        Hepatitis D, drugs and toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        Hepatitis E, EBV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F",
"       </td>",
"       <td>",
"        Fatty Infiltration - acute fatty liver of pregnancy, Reye's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G&nbsp;",
"       </td>",
"       <td>",
"        Genetic - Wilson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H",
"       </td>",
"       <td>",
"        Hypoperfusion (ischemic hepatitis, VOD, sepsis), HELLP syndrome, HSV, heat stroke, hepatectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Infiltration by tumor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMV: cytomegalovirus; EBV: Epstein-Barr virus; HELLP: hemolysis, elevated liver enzymes, low platelets; HSV: herpes simplex virus; VOD: veno-occlusive disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Uncommon indications for liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of Disease",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"1\">",
"        Causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Hepatic tumors",
"       </td>",
"       <td>",
"        Carcinoid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelioid hemangioendothelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrolamellar hepatoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatocellular carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic islet cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Metabolic and genetic disorders",
"       </td>",
"       <td>",
"        Alpha-1-antitrypsin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycogen storage diseases I and IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crigler-Najjar syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hypercholesterolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Galactosemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemophilia A and B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Byler's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homozygous hyperlipidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Vascular disorders",
"       </td>",
"       <td>",
"        Budd-Chiari syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Veno-occlusive disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        Miscellaneous",
"       </td>",
"       <td>",
"        Adult polycystic liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alagille syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodular regenerative hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caroli's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe graft-versus-host disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphangiomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic trauma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lopez, RR, Howard, TK, Villamil, FG, et al. Liver transplantation. In: Liver and Biliary diseases, Kaplowitz, N (Ed), 1996, p. 629, and Rosen, HR, Shackleton, CR, Martin, P, Med Clin North Am 1996; 80:1069.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12157=[""].join("\n");
var outline_f11_55_12157=null;
var title_f11_55_12158="Meningitis treatment based on susceptibility";
var content_f11_55_12158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for specific antimicrobial therapy of bacterial meningitis based on isolated pathogen and susceptibility testing*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microorganism, susceptibility",
"       </td>",
"       <td class=\"subtitle1\">",
"        Standard therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternative therapies",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Penicillin MIC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &le;0.06 mcg/mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        Penicillin G or ampicillin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , chloramphenicol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        &ge;0.12 mcg/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        MIC &lt;1.0 mcg/mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cefepime, meropenem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        MIC &ge;1.0 mcg/mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        Vancomycin plus a third-generation cephalosporin",
"        <sup>",
"         &Delta;&sect;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Fluoroquinolone",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Penicillin MIC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &lt;0.1 mcg/mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        Penicillin G or ampicillin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , chloramphenicol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        0.1-1.0 mcg/mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Chloramphenicol, fluoroquinolone, meropenem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Ampicillin",
"        <sup>",
"         ",
"        </sup>",
"        or penicillin G",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus agalactiae",
"        </em>",
"       </td>",
"       <td>",
"        Ampicillin",
"        <sup>",
"         ",
"        </sup>",
"        or penicillin G",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Escherichia coli",
"        </em>",
"        and other Enterobacteriaceae",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Aztreonam, fluoroquinolone, meropenem, trimethoprim-sulfamethoxazole, ampicillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Cefepime",
"        <sup>",
"         ",
"        </sup>",
"        or ceftazidime",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Aztreonam",
"        <sup>",
"         ",
"        </sup>",
"        , ciprofloxacin",
"        <sup>",
"         ",
"        </sup>",
"        , meropenem",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Beta-lactamase negative",
"       </td>",
"       <td class=\"sublist_other\">",
"        Ampicillin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , cefepime, chloramphenicol, fluoroquinolone, aztreonam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Beta-lactamase positive",
"       </td>",
"       <td class=\"sublist_other\">",
"        Third-generation cephalosporin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cefepime, chloramphenicol, fluoroquinolone, aztreonam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Methicillin susceptible",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nafcillin or oxacillin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Vancomycin, meropenem, linezolid, daptomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Methicillin resistant",
"       </td>",
"       <td class=\"sublist_other\">",
"        Vancomycin**",
"       </td>",
"       <td class=\"sublist_other\">",
"        Trimethoprim-sulfamethoxazole, linezolid, daptomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Staphylococcus epidermidis",
"        </em>",
"       </td>",
"       <td>",
"        Vancomycin**",
"       </td>",
"       <td>",
"        Linezolid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <em>",
"         Enterococcus",
"        </em>",
"        species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ampicillin susceptible",
"       </td>",
"       <td class=\"sublist_other\">",
"        Ampicillin plus gentamicin",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ampicillin resistant",
"       </td>",
"       <td class=\"sublist_other\">",
"        Vancomycin plus gentamicin",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ampicillin and vancomycin resistant",
"       </td>",
"       <td class=\"sublist_other\">",
"        Linezolid",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    MIC: Minimum inhibitory concentration",
"    <div class=\"footnotes\">",
"     * For recommended dosages, see the table on the recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      There may not be clinical data to support all recommendations for alternative antibiotics in patients with bacterial meningitis, but specific agents are recommended based on cerebrospinal fluid (CSF) penetration in experimental animal models and in vitro activity against the offending organism.",
"      <br>",
"       &Delta; Ceftriaxone or cefotaxime.",
"       <br>",
"        &loz;&nbsp;Consider addition of rifampin if the MIC of ceftriaxone is &gt;4 mcg/mL.",
"        <br>",
"         &sect;&nbsp;Moxifloxacin is recommended given its excellent CSF penetration and in vitro activity against",
"         <em>",
"          Streptococcus pneumoniae",
"         </em>",
"         , although there are no clinical data available. If used, many authorities would combine moxifloxacin with vancomycin or a third-generation cephalosporin (cefotaxime or ceftriaxone).",
"         <br>",
"          &yen;&nbsp;Addition of an aminoglycoside should be considered.",
"          <br>",
"           &Dagger;&nbsp;Choice of a specific antimicrobial regimen must be guided by in vitro susceptibility test results.",
"           <br>",
"            &dagger;&nbsp;Consider addition of rifampin.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12158=[""].join("\n");
var outline_f11_55_12158=null;
var title_f11_55_12159="Bronchial atresia CT";
var content_f11_55_12159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchial atresia in adult with incidental left lower lobe nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan of lower chest shows a left lower lobe nodule with surrounding halo of hyperlucency. The nodule represents mucoid impaction in the posterobasal segment of the left lower lobe with air-trapping in the surrounding lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_55_12159=[""].join("\n");
var outline_f11_55_12159=null;
